

AE

(19)



Europäisches Patentamt

European Patent Office

Office européen des brevets



(11)

EP 0 941 994 B1

(12)

EUROPEAN PATENT SPECIFICATION

(45) Date of publication and mention
of the grant of the patent:
14.05.2003 Bulletin 2003/20

(51) Int Cl.7: **C07D 487/04, A61K 31/505,
A61K 31/53, C07D 495/04**

(21) Application number: **99102872.1**

(22) Date of filing: **03.03.1999**

(54) Pyrazolopyrimidines and pyrazolotriazines with 5-HT6 receptor affinity

Pyrazolopyrimidine- und Pyrazolotriazinederivate mit einer Affinität für 5-HT6-Rezeptoren

Pyrazolopyrimidines et pyrazolotriazines ayant une affinité pour les récepteurs du 5-HT6

(84) Designated Contracting States:
**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE**
Designated Extension States:
LT LV RO SI

(74) Representative: **Poppe, Regina et al**
F.Hoffmann-La Roche AG
Patent Department (PLP),
124 Grenzacherstrasse
4070 Basel (CH)

(30) Priority: **11.03.1998 EP 98104346**

(56) References cited:
EP-A- 0 301 919 WO-A-97/11075
WO-A-98/27058 WO-A-98/27081
WO-A-99/02502 DE-A- 3 825 043

(73) Proprietor: **F. HOFFMANN-LA ROCHE AG**
4070 Basel (CH)

(72) Inventors:
• **Boes, Michael**
4310 Rheinfelden (CH)
• **Riemer, Claus**
79110 Freiburg (DE)
• **Stadler, Heinz**
4310 Rheinfelden (CH)


• **KIRKPATRICK W E ET AL:**
"3-HALO-5,7-DIMETHYLPYRAZOLO
1,5-APYRIMIDINES, A NONBENZODIAZEPINOID
CLASS OF ANTIANXIETY AGENTS DEVOID OF
POTENTIATION OF CENTRAL NERVOUS
SYSTEM DEPRESSANT EFFECTS OF ETHANOL
OR BARBITURATES" JOURNAL OF MEDICINAL
CHEMISTRY, vol. 77, no. 3, 1 March 1977, pages
386-393, XP002029041

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 0 941 994 B1

Description

[0001] The present invention is concerned with pyrazolopyrimidines and pyrazolotriazines of the general formulae



wherein

- R¹ signifies phenyl, optionally substituted by one or more C₁₋₇-alkyl, halogen or C₁₋₇-alkoxy or is tolyl, pyridyl, naphthyl or thiophenyl;
- R² signifies hydrogen, C₁₋₇-alkyl, C₁₋₇-thioalkyl or hydroxy-C₁₋₇-alkoxy;
- R³ signifies amino, C₁₋₇-alkylamino, di-C₁₋₇-alkyl-amino, piperazinyl, optionally substituted by one or more C₁₋₇-alkyl, benzyl, phenyl or hydroxy-C₁₋₇-alkyl or is morpholinyl, imidazolyl, (CH₃)₂N(CH₂)_nO- or morpholinyl-(CH₂)_nO- in which n signifies 2 or 3;
- R⁴ signifies hydrogen, C₁₋₇-alkyl or hydroxy-C₁₋₇-alkyl;
- R⁵ signifies hydrogen, halogen, C₁₋₇-alkyl, C₃₋₆-cycloalkyl, C₁₋₇-alkyl-C₁₋₇-alkoxy, OH-CH₂-CH₂-O-, (CH₃)₂N(CH₂)_nNH-, piperazinyl, optionally substituted by C₁₋₇-alkyl or is methyl-piperazinyl, optionally substituted by C₁₋₇-alkyl or is morpholinyl, methyl-morpholinyl, di-C₁₋₇-alkylamino or di-C₁₋₇-alkylamino-C₁₋₇-alkyl, or
- R⁴ and R⁵ together signify a group -(CH₂)_m- or -CH₂-S-CH₂- with m = 3 or 4,

as well as with their pharmaceutically acceptable salts.

[0002] These compounds surprisingly have a selective affinity to 5HT-6 receptors. They are accordingly suitable for the treatment and prevention of central nervous disorders such as, for example, psychoses, schizophrenia, manic depressions (Bryan L. Roth et al., J. Pharmacol. Exp. Ther., **268**, pages 1403-1410 (1994)), depressions (David R. Sibley et al., Mol. Pharmacol., **43**, pages 320-327 (1993)), neurological disorders (Anne Bourson et al., J. Pharmacol. Exp. Ther., **274**, pages 173-180 (1995); R. P. Ward et al., Neuroscience, **64**, pages 1105-1110 (1995)), memory disorders, Parkinson's disease, amyotrophic lateral sclerosis, Alzheimer's disease and Huntington's chorea (Andrew J. Sleight et al., Neurotransmissions, **11**, pages 1-5 (1995)).

[0003] The following prior art documents are known with regard to the subject matter of the present invention: (1) WO 99/02502, (2) WO98/27081, (3) WO98/27058, (4) WO97/11705, (5) DE 3825043, (6) EP 301919 and (7) J. Med. Chem., 1977, 386-393. The intermediate prior art documents (1) - (3) disclose compounds having a different fused heterocyclic ring with regard to the present invention. Compounds, described in documents (4) - (7) are different in view of the group R¹.

[0004] Objects of the present invention are the novel compounds of formulae I-A and I-B and their pharmaceutically useable salts per se, their use as therapeutically active substances, their manufacture, medicaments containing one or more of these compounds, optionally in the form of one of their pharmaceutically useable salts, as well as the production of such medicaments.

[0005] The following compounds are preferred for a use of the kind described above.

[0006] Especially preferred compounds of general formula I-A are those in which R³ signifies amino, such as, for example

- 3-benzenesulphonyl-5-methyl-2-methylsulphonyl-pyrazolo[1,5-a]pyrimidin-7-ylamine,
 3-(4-isopropyl-benzenesulphonyl)-5-methyl-2-methylsulphonyl-pyrazolo[1,5-a]pyrimidin-7-ylamine,
 5-methyl-2-methylsulphonyl-3-(naphthalene-2-sulphonyl)-pyrazolo[1,5-a]pyrimidin-7-ylamine,
 3-(4-fluoro-benzenesulphonyl)-5-methyl-2-methylsulphonyl-pyrazolo[1,5-a]pyrimidin-7-ylamine,
 3-benzenesulphonyl-5-cyclopropyl-2-methylsulphonyl-pyrazolo[1,5-a]pyrimidin-7-ylamine,

3-benzenesulphonyl-2-methylsulphanyl-6,7-dihydro-5H-cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-ylamine,
 3-benzenesulphonyl-5-isopropyl-2-methylsulphanyl-pyrazolo[1,5-a]pyrimidin-7-ylamine,
 5-methyl-2-methylsulphanyl-3-(toluene-2-sulphonyl)-pyrazolo[1,5-a]pyrimidin-7-ylamine,
 5-methyl-2-methylsulphanyl-3-(toluene-3-sulphonyl)-pyrazolo[1,5-a]pyrimidin-7-ylamine,
 3-benzenesulphonyl-5-methoxymethyl-2-methylsulphanyl-pyrazolo[1,5-a]pyrimidin-6-ylamine,
 3-benzenesulphonyl-N5,N5-dimethyl-2-methylsulphanyl-pyrazolo[1,5-a]pyrimidin-5,7-diamine,
 3-benzenesulphonyl-N5-(2-dimethylamino-ethyl)-2-methylsulphanyl-pyrazolo[1,5-a]pyrimidin-5,7-diamine,
 3-benzenesulphonyl-5-(4-methyl-piperazin-1-yl)-2-methylsulphanyl-pyrazolo[1,5-a]pyrimidin-7-ylamine and
 3-benzenesulphonyl-5-dimethylamineomethyl-2-methylsulphanyl-pyrazolo[1,5-a]pyrimidin-7-ylamine.

[0007] Furthermore, compounds are preferred in which in formula I-A R³ signifies piperazinyl, such as, for example,
 3-benzenesulphonyl-5-methyl-2-methylsulphanyl-7-piperazin-1-yl-pyrazolo[1,5-a]pyrimidine,
 3-(4-tert-butyl-benzenesulphonyl)-5-methyl-2-methylsulphanyl-7-piperazin-1-yl-pyrazolo[1,5-a]pyrimidine,
 3-benzenesulphonyl-5,6-dimethyl-2-methylsulphanyl-7-piperazin-1-yl-pyrazolo[1,5-a]pyrimidine,
 3-benzenesulphonyl-2-methylsulphanyl-7-piperazin-1-yl-5-propyl-pyrazolo[1,5-a]pyrimidine,
 3-benzenesulphonyl-5-cyclopropyl-2-methylsulphanyl-7-piperazin-1-yl-pyrazolo[1,5-a]pyrimidine,
 3-benzenesulphonyl-2-methylsulphanyl-8-piperazin-1-yl-6,7-dihydro-5H-cyclopenta[d]pyrazolo[1,5-a]pyrimi-

dine,
 3-benzenesulphonyl-2-methylsulphanyl-8-piperazin-1-yl-5H,7H-pyrazolo[1,5-a]thieno[3,4-d]pyrimidine,
 5-methyl-2-methylsulphanyl-7-piperazin-1-yl-3-(thiophen-2-sulphonyl)-pyrazolo[1,5-a]pyrimidine,
 3-benzenesulphonyl-2-ethyl-8-piperazin-1-yl-6,7-dihydro-5H-cyclopenta[d]pyrazolo[1,5-a]pyrimidine and
 5-methyl-2-methylsulphanyl-7-piperazin-1-yl-3-(toluol-2-sulphonyl)-pyrazolo[1,5-a]pyrimidine.

[0008] Moreover, of the already mentioned there are preferred compounds of formulae I-A in which R³ signifies methylpiperazinyl, such as, for example,

3-benzenesulphonyl-5-cyclopropyl-2-methylsulphanyl-7-(4-methylpiperazin-1-yl)-pyrazolo[1,5-a]pyrimidine,
 3-benzenesulphonyl-8-(4-methyl-piperazin-1-yl)-2-methylsulphanyl-6,7-dihydro-5H-cyclopenta[d]pyrazolo
 [1,5-a]pyrimidine,
 3-benzenesulphonyl-8-(4-methyl-piperazin-1-yl)-2-methylsulphanyl-5H,7H-pyrazolo[1,5-a]thieno[3,4-d]pyrimi-
 dine,
 3-benzenesulphonyl-5-isopropyl-7-(4-methyl-piperazin-1-yl)-2-methylsulphanyl-pyrazolo[1,5-a]pyrimidine and
 2-[3-benzenesulphonyl-7-(4-methyl-piperazin-1-yl)-2-methylsulphanyl-pyrazolo[1,5-a]pyrimidine-5-yloxy]-etha-
 nol.

[0009] Preferred are further compounds of formula I-B, wherein R³ signifies amino or methylpiperazinyl, for example the following compounds:

8-Benzenesulphonyl-7-methylsulphanyl-pyrazolo[1,5-a][1,3,5]triazin-4-ylamine and 8-benzenesulphonyl-2-me-
 thyl-4-(4-methylpiperazin-1-yl)-7-methylsulphanyl-pyrazolo[1,5-a][1,3,5]triazine.

[0010] The term "lower alkyl" used in the present description denotes residues from 1 to 7, preferably from 1 to 4, carbon atoms, such as, for example, methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl and t-butyl.

[0011] The term "lower alkoxy" denotes a lower alkyl residue in the sense of the foregoing definition bonded via an oxygen atom, such as, for example, methoxy, ethoxy, n-propoxy, i-propoxy, n-butoxy, i-butoxy and t-butoxy.

[0012] The term "lower alkylamino" denotes a lower alkyl residue in the sense of the foregoing definition bonded via a NH group, such as, for example, methylamino and ethylamino.

[0013] The term "di-lower-alkylamino" denotes to identical or different lower alkyl residues in the sense of the foregoing definition bonded via a nitrogen atom, such as, for example, dimethylamino, diethylamino or methyl-ethyl-amino.


[0014] The term "halogen" embraces fluorine, chlorine, bromine and iodine.

[0015] The term "lower thioalkyl" denotes a lower alkyl residue in the sense of the foregoing bonded via a sulphur atom.


[0016] The manufacture of the novel compounds can be effected in a manner known per se; that of formula I-A is described in Examples 1-119 and that of formula I-B is described in Examples 120-125. Moreover, Schemes 1-3 provide a general overview with respect to the possibilities available for the preparation of these novel compounds, with the starting compounds of formula III in Scheme 1 being known from the literature or being preparable in analogy to described methods.

[0017] The compounds of formulae I-A and I-B also embrace those compounds in which hydrogen can be replaced by tritium.

[0018] The compounds of formulae I-A and I-B can be manufactured by reacting a compound of the formula



10 or a compound of the formula



with a compound of the formula



wherein R^1 - R^5 have the significances described above, and optionally converting a compound of general formula I-A or I-B into a pharmaceutically acceptable salt.

30 **[0019]** The reaction of a compound of formulae X or XIV with a compound of the formula HR^3 is effected according to methods known per se. Conveniently, a compound of formulae X or XIV is dissolved in DMF and depending on the reaction partner, which can be dissolved in DMF or an alcohol, reacted at room temperature or at the boiling temperature of the solvent used. Especially preferred reaction partners for the compounds of formulae X or XIV are piperazine, 1-methyl-piperazine, NH_3 , methylamine, dimethylamine, morpholine, imidazole, N-benzylpiperidine, 1-(2-hydroxyethyl)-piperazine, 1-phenylpiperazine, 2-dimethylaminoethylamine or cis-2,6-dimethylpiperazine.

35 **[0020]** The compounds of formulae I-A and I-B can subsequently converted into pharmaceutically acceptable salts. Not only salts with inorganic acids, but also salts with organic acids come into consideration. Examples from the large number of such salts are hydrochlorides, hydrobromides, sulphates, nitrates, citrates, acetates, maleates, succinates, methanesulphonates, p-toluenesulphonates and the like. These salts can be manufactured according to methods which are known per se and which will be familiar to any person skilled in the art.

40

45

50

55

Scheme 1

5

10

15

20


25

30

35

40

45



wherein R¹ has the significance given above.

50

55

Scheme 2


5

10

15

20

25



wherein R^1 , R^2 , R^3 and R^4 have the significance set forth above.

Scheme 3

30


35

40

45

50

55



wherein R¹, R², R³ and R⁵ have the significances set forth above.

[0021] The following compounds of formula I-A were manufactured according to Examples 1-123:

Example No.	R ¹	R ²	R ³	R ⁴	R ⁵
1	Ph	SCH ₃	Piperazinyl	H	CH ₃
2	Ph	SCH ₃	MePiperazinyl	H	CH ₃
3	Ph	SCH ₃	NHCH ₃	H	CH ₃
4	Ph	SCH ₃	NH ₂	H	CH ₃
5	Ph	SCH ₃	N(CH ₃) ₂	H	CH ₃
6	Ph	SCH ₃	Morpholinyl		CH ₃
7	Ph	SCH ₃	Imidazolyl	H	CH ₃
8	Ph	SCH ₃	Benzylpiperazinyl	H	CH ₃
9	Ph	SCH ₃	Hydroxyethylpiperazinyl	H	CH ₃
10	Ph	SCH ₃	Phenylpiperazinyl	H	CH ₃
11	Ph	SCH ₃	(CH ₃) ₂ N-CH ₂ CH ₂ NH	H	CH ₃
12	Ph	SCH ₃	2,6-Dimethylpiperazinyl	H	CH ₃
13	4-CH ₃ -Ph	SCH ₃	Piperazinyl	H	CH ₃
14	4-CH ₃ -Ph	SCH ₃	MePiperazinyl	H	CH ₃
15	4-CH ₃ -Ph	SCH ₃	NHCH ₃	H	CH ₃
16	4-CH ₃ -Ph	SCH ₃	NH ₂	H	CH ₃
17	4-CH ₃ -Ph	SCH ₃	N(CH ₃) ₂	H	CH ₃
18	4-(CH ₃) ₂ CHPh	SCH ₃	Piperazinyl	H	CH ₃
19	4-(CH ₃) ₂ CHPh	SCH ₃	MePiperazinyl	H	CH ₃
20	4-(CH ₃) ₂ CHPh	SCH ₃	NH ₂	H	CH ₃
21	4-(CH ₃) ₂ CHPh	SCH ₃	N(CH ₃) ₂	H	CH ₃
22	4-t-Bu-Ph	SCH ₃	Piperazinyl	H	CH ₃
23	4-t-Bu-Ph	SCH ₃	MePiperazinyl	H	CH ₃
24	4-t-Bu-Ph	SCH ₃	NH ₂	H	CH ₃
25	4-Cl-Ph	SCH ₃	Piperazinyl	H	CH ₃
26	4-Cl-Ph	SCH ₃	MePiperazinyl	H	CH ₃
27	4-Cl-Ph	SCH ₃	NH ₂	H	CH ₃
28	4-Cl-Ph	SCH ₃	N(CH ₃) ₂	H	CH ₃
29	2,4-Di-Cl-Ph	SCH ₃	Piperazinyl	H	CH ₃
30	2,4-Di-Cl-Ph	SCH ₃	MePiperazinyl	H	CH ₃
31	2,4-Di-Cl-Ph	SCH ₃	NH ₂	H	CH ₃
32	4-Br-Ph	SCH ₃	Piperazinyl	H	CH ₃
33	4-Br-Ph	SCH ₃	MePiperazinyl	H	CH ₃
34	4-Br-Ph	SCH ₃	NH ₂	H	CH ₃
35	4-MeO-Ph	SCH ₃	Piperazinyl	H	CH ₃
36	4-MeO-Ph	SCH ₃	MePiperazinyl	H	CH ₃

(continued)

Example N .	R ¹	R ²	R ³	R ⁴	R ⁵
37	4-MeO-Ph	SCH ₃	NH ₂	H	CH ₃
38	2-Naphthyl	SCH ₃	MePiperazinyl	H	CH ₃
39	2-Naphthyl	SCH ₃	N(CH ₃) ₂	H	CH ₃
40	2-Naphthyl	SCH ₃	NH ₂	H	CH ₃
41	4-F-Ph	SCH ₃	Piperazinyl	H	CH ₃
42	4-F-Ph	SCH ₃	MePiperazinyl	H	CH ₃
43	4-F-Ph	SCH ₃	NH ₂	H	CH ₃
44	4-I-Ph	SCH ₃	NH ₂	H	CH ₃
45	Ph	SCH ₃	Piperazinyl	CH ₃	CH ₃
46	Ph	SCH ₃	MePiperazinyl	CH ₃	CH ₃
47	Ph	SCH ₃	Piperazinyl	H	n-Propyl
48	Ph	SCH ₃	MePiperazinyl	H	n-Propyl
49	Ph	SCH ₃	Piperazinyl	H	Cyclo-propyl
50	Ph	SCH ₃	MePiperazinyl	H	Cyclo-propyl
51	Ph	SCH ₃	NH ₂	H	Cyclo-propyl
52	Ph	SCH ₃	Piperazinyl	CH ₂ CH ₂ CH ₂	
53	Ph	SCH ₃	MePiperazinyl	CH ₂ CH ₂ CH ₂	
54	Ph	SCH ₃	NH ₂	CH ₂ CH ₂ CH ₂	
55	Ph	SCH ₃	Piperazinyl	CH ₂ CH ₂ CH ₂ CH ₂	
56	Ph	SCH ₃	MePiperazinyl	CH ₂ CH ₂ CH ₂ CH ₂	
57	Ph	SCH ₃	Piperazinyl	CH ₂ SCH ₂	
58	Ph	SCH ₃	MePiperazinyl	CH ₂ SCH ₂	
59	Thiophenyl	SCH ₃	Piperazinyl	H	CH ₃
60	Thiophenyl	SCH ₃	MePiperazinyl	H	CH ₃
61	Thiophenyl	SCH ₃	NH ₂	H	CH ₃
62	Ph	SCH ₃	MePiperazinyl	H	i-Propyl
63	Ph	SCH ₃	NH ₂	H	i-Propyl
64	Ph	SCH ₃	Piperazinyl	H	t-Butyl
65	Ph	Ethyl	Piperazinyl	H	CH ₃
66	Ph	Ethyl	MePiperazinyl	H	CH ₃
67	Ph	Ethyl	(CH ₃) ₂ N-CH ₂ CH ₂ NH	H	CH ₃
68	4-Br-Ph	Ethyl	Piperazinyl	H	CH ₃
69	4-Br-Ph	Ethyl	MePiperazinyl	H	CH ₃
70	4-Br-Ph	Ethyl	(CH ₃) ₂ N-CH ₂ CH ₂ NH	H	CH ₃
71	4-MeO-Ph	Ethyl	Piperazinyl	H	CH ₃
72	4-MeO-Ph	Ethyl	MePiperazinyl	H	CH ₃
73	4-MeO-Ph	Ethyl	NH ₂	H	CH ₃

(continued)

Example No.	R ¹	R ²	R ³	R ⁴	R ⁵
5 74	4-MeO-Ph	Ethyl	2,6-DimethylpiperazinyI	H	CH ₃
75	Ph	Ethyl	PiperazinyI	CH ₂ CH ₂ CH ₂	
76	Ph	Ethyl	MePiperazinyI	CH ₂ CH ₂ CH ₂	
10 77	Ph	Ethyl	NH ₂	CH ₂ CH ₂ CH ₂	
78	Ph	Ethyl	2,6-DimethylpiperazinyI	CH ₂ CH ₂ CH ₂	
79	Ph	H	PiperazinyI	H	CH ₃
80	Ph	H	MePiperazinyI	H	CH ₃
15 81	o-Tolyl	SCH ₃	PiperazinyI	H	CH ₃
82	o-Tolyl	SCH ₃	MePiperazinyI	H	CH ₃
83	o-Tolyl	SCH ₃	NH ₂	H	CH ₃
20 84	m-Tolyl	SCH ₃	PiperazinyI	H	CH ₃
85	m-Tolyl	SCH ₃	MePiperazinyI	H	CH ₃
86	m-Tolyl	SCH ₃	NH ₂	H	CH ₃
25 87	3-Pyridyl	SCH ₃	PiperazinyI	H	CH ₃
88	3-Pyridyl	SCH ₃	MePiperazinyI	H	CH ₃
89	3-Pyridyl	SCH ₃	NH ₂	H	CH ₃
90	Ph	SCH ₃	MePiperazinyI	CH ₂ CH ₂ OH	CH ₃
30 91	Ph	OCH ₂ CH ₂ OH	MePiperazinyI	H	CH ₃
92	Ph	SCH ₃	PiperazinyI	H	CH ₂ CH ₂ O-CH ₃
93	Ph	SCH ₃	MePiperazinyI	H	CH ₂ CH ₂ O-CH ₃
94	Ph	SCH ₃	NH ₂	H	CH ₂ CH ₂ O-CH ₃
35 95	Ph	SCH ₃	PiperazinyI	H	CH ₂ OCH ₃
96	Ph	SCH ₃	MePiperazinyI	H	CH ₂ OCH ₃
97	Ph	SCH ₃	NH ₂	H	CH ₂ OCH ₃
40 98	Ph	SCH ₃	MePiperazinyI	H	Cl
99	Ph	SCH ₃	MePiperazinyI	H	H
100	Ph	SCH ₃	MePiperazinyI	H	OCH ₂ CH ₂ OH
101	Ph	SCH ₃	NH ₂	H	Cl
45 102a	Ph	SCH ₃	NH ₂	H	N(CH ₃) ₂
102b	Ph	SCH ₃	NH ₂	H	NHCH ₂ CH ₂ . N (CH ₃) ₂
50 103	Ph	SCH ₃	NH ₂	H	MePiperazinyI
104	Ph	Ethyl	MePiperazinyI	H	Cl
105	Ph	Ethyl	MePiperazinyI	H	H
106	Ph	Ethyl	MePiperazinyI	H	MePiperazinyI
55 107	Ph	Ethyl	MePiperazinyI	H	MorpholinyI
108	Ph	Ethyl	MePiperazinyI	H	OCH ₂ CH ₂ OH

(continued)

Exempl No.	R ¹	R ²	R ³	R ⁴	R ⁵
109a	Ph	Ethyl	MePiperazinyI	H	N(CH ₃) ₂
109b	Ph	Ethyl	MePiperazinyI	H	NHCH ₂ CH ₂ N-(CH ₃) ₂
110	Ph	Ethyl	NH ₂	H	Cl
111	Ph	Ethyl	NH ₂	H	MePiperazinyI
112a	Ph	Ethyl	NH ₂	H	N(CH ₃) ₂
112b	Ph	Ethyl	NH ₂	H	NHCH ₂ CH ₂ N-(CH ₃) ₂
113	Ph	SCH ₃	NH ₂	H	CH ₂ N(CH ₃) ₂
114	Ph	SCH ₃	NH ₂	H	CH ₂ NHMePip
115	Ph	SCH ₃	MePiperazinyI	H	CH ₂ NHMePip
116	Ph	SCH ₃	NH ₂	H	CH ₂ Morph
117	Ph	SCH ₃	MePiperazinyI	H	CH ₂ Morph
118	Ph	SCH ₃	O(CH ₂)N(CH ₃) ₂	H	CH ₃
119	Ph	SCH ₃	O(CH ₂) ₂ morpholinyl	H	CH ₃

[0022] The following compounds of formula I-B were manufactured in accordance with Synthesis Examples 120 - 125:

Example No.	R ¹	R ²	R ³	R ⁵
120	Ph	SCH ₃	NH ₂	H
121	Ph	SCH ₃	NHCH ₃	CH ₃
122	Ph	SCH ₃	N(CH ₃) ₂	CH ₃
123	Ph	SCH ₃	NH(CH ₂) ₃ N-(CH ₃) ₂	CH ₃
124	Ph	SCH ₃	MePiperazinyI	CH ₃
125	Ph	SCH ₃	BenzylpiperazinyI	CH ₃

[0023] As mentioned earlier, the compounds of formulae I-A and I-B are novel. They have pharmacological properties and possess only a low toxicity. They have as a common feature they pronounced affinity to 5-HT₆ receptors and, on the basis of their action at this receptor, are suitable for the treatment or prevention of central nervous disorders such as, for example, psychoses, schizophrenia, manic depressions, neurological disorders, memory disorders, Parkinson's disease, amyotrophic lateral sclerosis, Alzheimer's disease and Huntington's chorea.

[0024] The binding of the compounds of formulae I-A and I-B in accordance with the invention to 5-HT₆ receptors was determined as follows.

[0025] Membranes obtained from HEK 1293 cells which had been transfected with 5-HT₆ receptors from rats were used.

[0026] The cells were purified by two-fold centrifugation (10 minutes at 3000 g) in phosphate buffer-sodium chloride solution. The cell mass was suspended in an ice-cold solution consisting of 50 mm Tris-HCl buffer, 10 mm MgCl₂, 0.5 mm EDTA and 0.1 mm phenylmethylsulphonyl fluoride and homogenized (Polytron homogenizer, 15 seconds at maximum speed). The homogenizate was incubated at 37°C for 10 minutes and subsequently centrifuged (20 minutes at 20 000 g). The cell mass was again suspended in the aforementioned Tris buffer solution. The cell concentration obtained was 4 x 10⁷ cells/ml. 1 ml aliquots of the homogenizate were frozen at -80°C.

[0027] Displacement experiments were carried out in order to determine the affinity of the test substance to the 5-HT₆ receptor. For the performance of the test, the homogenizate was thawed and suspended in a buffer solution (pH 7.4) consisting of 50 mm Tris-HCl buffer, 5 mm MgCl₂, 10⁻⁵ M pargyline and 0.1% ascorbic acid. 100 µl of membrane

suspension, 50 μ l of [3 H]-LSD (specific activity 85Ci/mMol, final concentration 1 NM) and 50 μ l of test substance solution were incubated at 37°C for 1 hour. The respective test substance was investigated at 7 different concentrations of 10^{-10} M to 10^{-4} M. The binding reaction of the test substance was interrupted by rapid filtration through a Whatmann GF/B filter. The filters were washed with 2 x 2 ml of Tris-HCl buffer (50 mm pH 7.4) and the radioactivity of the filter was measured by scintillation spectroscopy in 2 ml of scintillation solution. All tests were carried out in triplicate and repeated three times. The pKi values ($pKi = -\log_{10}Ki$) of the test substances have been determined. The Ki value is defined by the following formula

$$Ki = \frac{IC_{50}}{1 + \frac{[L]}{K_D}}$$

in which the IC_{50} values are those concentrations of the test compounds in NM by which 50% of the ligands bonded to the receptor are displaced. [L] is the concentration of the ligand and the K_D value is the dissociation constant of the ligand.

[0028] The compounds in accordance with the invention have a selective affinity to 5-HT₆ receptors with a pKi value between 6.5 and 9.5.

[0029] The compounds of formulae I-A and I-B and the pharmaceutically acceptable salts of the compounds of formulae I-A and I-B can be used as medicaments, e.g. in the form of pharmaceutical preparations. The pharmaceutical preparations can be administered orally e.g. in the form of tablets, coated tablets, dragées, hard and soft gelatine capsules, solutions, emulsions or suspensions. However, the administration can also be effected rectally, e.g. in the form of suppositories, or parentally, e.g. in the form of injection solutions.

[0030] For the production of pharmaceutical preparations, the compounds of formulae I-A and I-B and the pharmaceutically acceptable salts of the compounds of formulae I-A and I-B can be processed with pharmaceutically inert, inorganic or organic carriers. Lactose, corn starch or derivatives thereof, talc, stearic acid or its salts and the like can be used as such carriers for tablets, coated tablets, dragées and hard gelatine capsules. Suitable carriers for soft gelatine capsules are, for example, vegetable oils, waxes, fats, semi-solid and liquid polyols and the like. Depending on the nature of the active ingredient no carriers are, however, usually required in the case of soft gelatine capsules. Suitable carriers for the production of solutions and syrups are, for example, water, polyols, glycerol, vegetable oils and the like. Suitable carriers for suppositories are, for example, natural or hardened oils, waxes, fats, semi-liquid or liquid polyols and the like.

[0031] Moreover, the pharmaceutical preparations can contain preservatives, solubilizers, stabilizers, wetting agents, emulsifiers, sweeteners, colorants, flavorants, salts for varying the osmotic pressure, buffers, masking agents or antioxidants. They can also contain still other pharmaceutically valuable substances.

[0032] Medicaments containing a compound of formula I-A or I-B or a pharmaceutically acceptable salt thereof and a therapeutically inert carrier are also an object of the present invention, as is a process for their production, which comprises bringing one or more compounds of formula I and/or pharmaceutically acceptable acid addition salts thereof and, if desired, one or more other therapeutically valuable substances together with one or more therapeutically inert carriers into a galenical administration form in a manner known per se.

[0033] In accordance with the invention compounds of general formulae I-A and I-B as well as their pharmaceutically acceptable salts can be used in the treatment or prevention of central nervous disorders, such as depressions, psychoses, schizophrenia, neurological disorders, memory disorders, Parkinson's disease, amyotrophic lateral sclerosis, Alzheimer's disease, Huntington's chorea and for the production of corresponding medicaments. The dosage can vary within wide limits and will, of course, be fitted to the individual requirements in each particular case. In the case of oral administration the dosage lies in a range of about 0.1 mg per dose to about 1000 mg per day of a compound of general formula I-A or I-B or the corresponding amount of a pharmaceutically acceptable salt thereof, although the upper limit can also be exceeded when this is shown to be indicated.

[0034] The following Examples serve to illustrate the present invention in more detail. However, they are not intended to limit its scope in any manner.

Example 1

3-Benzenesulphonyl-5-methyl-2-methylsulphanyl-7-piperazin-1-yl-pyrazolo[1,5-a]pyrimidine

[0035]

a) A solution of 6.30 g (21 mmol) of 4-benzenesulphonyl-5-methylsulphanyl-2H-pyrazol-3-ylamine and 3.24 ml

(25.8 mmol) of ethyl acetoacetate in 20 ml of acetic acid was heated at reflux for 1.5 hrs. The reaction solution was cooled to 0°C and stirred at this temperature for 30 min. The separated crystals were filtered off under suction and dried at 50°/10 Torr. There were thus obtained 6.10 g (87%) of 3-benzenesulphonyl-5-methyl-2-methylsulphanyl-pyrazolo[1,5-a]pyrimidin-7-ol as white crystals, m.p. > 220°.

b) A suspension of 3.0 g (8.94 mmol) of 3-benzenesulphonyl-5-methyl-2-methylsulphanyl-pyrazolo[1,5-a]pyrimidin-7-ol in 20 ml of POCl₃ was heated at reflux for 45 min. The reaction solution was cooled to RT and evaporated in a high vacuum. The residue was treated with 100 ml of ice-water and the pH value of the solution was adjusted to 8 with sat. NaHCO₃ solution. The aqueous phase was extracted three times with 100 ml of CH₂Cl₂, and the organic phases were dried (MgSO₄), filtered and evaporated. Chromatography (SiO₂, CH₂Cl₂/AcOEt 19:1) of the residue yielded 3.0 g (94%) of 3-benzenesulphonyl-7-chloro-5-methyl-2-methylsulphanyl-pyrazolo[1,5-a]pyrimidine as pale yellow crystals, m.p. 163-165°C.

c) 0.3 g (3.4 mmol) of piperazine in 10 ml of DMF was added to a solution of 0.6 g (1.7 mmol) of 3-benzenesulphonyl-7-chloro-5-methyl-2-methylsulphanyl-pyrazolo[1,5-a]pyrimidine in 10 ml of DMF and the mixture was stirred at 60°C for 2 hrs. The reaction solution was cooled to RT and evaporated in a high vacuum. The residue was partitioned between 2N NaOH and CH₂Cl₂. The aqueous phase was extracted three times with CH₂Cl₂, and the combined organic phases were dried (MgSO₄), filtered and evaporated. Subsequent chromatography (SiO₂, CH₂Cl₂/MeOH 8:1) and crystallization from EtOH yielded 0.35 g (51%) of 3-benzenesulphonyl-5-methyl-2-methylsulphanyl-7-piperazin-1-yl-pyrazolo[1,5-a]pyrimidine as colourless crystals, m.p. 201-202°.

Example 2

3-Benzenesulphonyl-5-methyl-7-(4-methyl-piperazin-1-yl)-2-methylsulphanyl-pyrazolo[1,5-a]pyrimidine

[0036] 0.15 g (1.5 mmol) of 1-methyl-piperazine in 10 ml of DMF was added to a solution of 0.45 g (1.275 mmol) of 3-benzenesulphonyl-7-chloro-5-methyl-2-methylsulphanyl-pyrazolo[1,5-a]pyrimidine in 10 ml of DMF and stirred at 60° for 2 hrs. The reaction solution was cooled to RT and evaporated in a high vacuum. The residue was partitioned between 2N NaOH and CH₂Cl₂. The aqueous phase was extracted three times with CH₂Cl₂, and the combined organic phases were dried (MgSO₄), filtered and evaporated. Subsequent chromatography (SiO₂, CH₂Cl₂/MeOH 15:1) and crystallization from EtOH yielded 0.40 g (75%) of 3-benzenesulphonyl-5-methyl-7-(4-methyl-piperazine-1-yl)-2-methylsulphanyl-pyrazolo[1,5-a]pyrimidine as colourless crystals, m.p. 209-210°.

Example 3

(3-Benzenesulphonyl-5-methyl-2-methylsulphanyl-pyrazolo[1,5-a]pyrimidin-7-yl)-methyl-amine

[0037] 10 ml of a 33% solution of methylamine in EtOH was added to a solution of 0.3 g (0.85 mmol) of 3-benzenesulphonyl-7-chloro-5-methyl-2-methylsulphanyl-pyrazolo[1,5-a]pyrimidine in 5 ml of DMF and stirred at RT for 2 hrs. The reaction solution was evaporated in a high vacuum and the residue was partitioned between 2N NaOH and CH₂Cl₂. The aqueous phase was extracted three times with CH₂Cl₂, and the combined organic phases were dried (MgSO₄), filtered and evaporated. Subsequent chromatography (SiO₂, CH₂Cl₂/AcOEt 15:1) and crystallization from EtOH yielded 0.18 g (60%) of (3-benzenesulphonyl-5-methyl-2-methylsulphanyl-pyrazolo[1,5-a]pyrimidin-7-yl)-methyl-amine as colourless crystals, m.p. > 230°.

Example 4

(3-Benzenesulphonyl-5-methyl-2-methylsulphanyl-pyrazolo[1,5-a]pyrimidin-7-yl)amine

[0038] 10 ml of a 50% solution of NH₃ in MeOH were added to a solution of 0.40 g (1.13 mmol) of 3-benzenesulphonyl-7-chloro-5-methyl-2-methylsulphanyl-pyrazolo[1,5-a]pyrimidine in 10 ml of DMF and stirred at RT for 2 hrs. The reaction solution was evaporated in a high vacuum and the residue was partitioned between 2N NaOH and CH₂Cl₂. The aqueous phase was extracted three times with CH₂Cl₂, and the combined organic phases were dried (MgSO₄), filtered and evaporated. Subsequent chromatography (SiO₂, CH₂Cl₂/AcOEt 7:1) and crystallization from EtOH yielded 0.25 g (66%) of (3-benzenesulphonyl-5-methyl-2-methylsulphanyl-pyrazolo[1,5-a]pyrimidin-7-yl)amine as colourless crystals, m.p. > 230°.

Example 5

[0039] (3-Benzenesulphonyl-5-methyl-2-methylsulphonyl-pyrazolo[1,5-a]pyrimidin-7-yl)-dimethyl-amine added to a solution of 0.30 g (0.85 mmol) 3-benzenesulphonyl-7-chloro-5-methyl-2-methylsulphonyl-pyrazolo[1,5-a]pyrimidine in 10 ml of DMF and stirred at RT for 1 hr. The reaction solution was evaporated in a high vacuum and the residue was partitioned between 2N NaOH and CH₂Cl₂. The aqueous phase was extracted three times with CH₂Cl₂, and the combined organic phases were dried (MgSO₄), filtered and evaporated. Subsequent chromatography (SiO₂, CH₂Cl₂/AcOEt 15:1) and crystallization from EtOH yielded 0.18 g (58%) of (3-benzene- sulphonyl-5-methyl-2-methylsulphonyl-pyrazolo[1,5-a]pyrimidin-7-yl)-dimethyl-amine as colourless crystals, m.p. > 230°.

Example 63-Benzenesulphonyl-5-methyl-2-methylsulphonyl-7-morpholin-4-yl-pyrazolo[1,5-a]pyrimidine

[0040] 0.20 g (2.2 mmol) of morpholine was added to a solution of 0.25 g (0.85 mmol) of 3-benzenesulphonyl-7-chloro-5-methyl-2-methylsulphonyl-pyrazolo[1,5-a]pyrimidine in 10 ml of DMF and stirred at 60° for 1 hr. The reaction solution was cooled to RT and evaporated in a high vacuum. The residue was partitioned between 2N NaOH and CH₂Cl₂. The aqueous phase was extracted three times with CH₂Cl₂, and the combined organic phases were dried (MgSO₄), filtered and evaporated. Subsequent chromatography (SiO₂, CH₂Cl₂/MeOH 25:1) and crystallization from EtOH yielded 0.20 g (70%) of 3-benzenesulphonyl-5-methyl-2-methylsulphonyl-7-morpholin-4-yl-pyrazolo[1,5-a]pyrimidine as colourless crystals, m.p. 206-208°.

Example 73-Benzenesulphonyl-7-imidazol-1-yl-5-methyl-2-methylsulphonyl-pyrazolo[1,5-a]pyrimidine

[0041] 0.08 g (1.5 mmol) of sodium methanolate was added to a suspension of 0.122 g (1.8 mmol) of imidazole in 30 ml of DMF and stirred at 60° for 15 min. Subsequently, a solution of 0.53 g (1.5 mmol) of 3-benzenesulphonyl-7-chloro-5-methyl-2-methylsulphonyl-pyrazolo[1,5-a]pyrimidine in 10 ml of DMF was added to this suspension and stirred at 60° for 1 hr. The reaction solution was cooled to RT and evaporated in a high vacuum. The residue was partitioned between 2N NaOH and CH₂Cl₂. The aqueous phase was extracted three times with CH₂Cl₂, and the combined organic phases were dried (MgSO₄), filtered and evaporated. Subsequent chromatography (SiO₂, CH₂Cl₂/MeOH 15:1) and crystallization from EtOH yielded 0.30 g (51%) of 3-benzenesulphonyl-7-imidazol-1-yl-5-methyl-2-methylsulphonyl-pyrazolo[1,5-a]pyrimidine as colourless crystal, m.p. >230°.

Example 83-Benzenesulphonyl-7-(4-benzyl-piperazin-1-yl)-5-methyl-2-methylsulphonyl-pyrazolo[1,5-a]pyrimidine

[0042] 0.35 g (2 mmol) of N-benzyl-piperidine was added to a solution of 0.35 g (1 mmol) of 3-benzenesulphonyl-7-chloro-5-methyl-2-methylsulphonyl-pyrazolo[1,5-a]pyrimidine in 5 ml of DMF and stirred at 60° for 2 hrs. The reaction solution was cooled to RT and evaporated in a high vacuum. The residue was partitioned between 2N NaOH and CH₂Cl₂. The aqueous phase was extracted three times with CH₂Cl₂, and the combined organic phases were dried (MgSO₄), filtered and evaporated. Subsequent chromatography (SiO₂, CH₂Cl₂/MeOH 19:1) and crystallization from EtOH yielded 0.36 g (73%) of 3-benzenesulphonyl-7-(4-benzyl-piperazin-1-yl)-5-methyl-2-methylsulphonyl-pyrazolo[1,5-a]pyrimidine as colourless crystals m.p. 156-158°.

Example 92-[4-(3-Benzenesulphonyl-5-methyl-methylsulphonyl-pyrazolo[1,5-a]pyrimidin-7-yl)-piperazin-1-yl]-ethanol

[0043] 0.26 g (2 mmol) of 1(2-hydroxyethyl)-piperazine was added to a solution of 0.35 g (1 mmol) of 3-benzenesulphonyl-7-chloro-5-methyl-2-methylsulphonyl-pyrazolo[1,5-a]pyrimidine and stirred at 60° for 2 hrs. The reaction solution was cooled to RT and evaporated in a high vacuum. The residue was partitioned between 2N NaOH and CH₂Cl₂. The aqueous phase was extracted three times with CH₂Cl₂, and the combined organic phases were dried (MgSO₄), filtered and evaporated. Subsequent chromatography (SiO₂, CH₂Cl₂/MeOH 19:1) and crystallization from EtOH yielded 0.36 g (73%) of 2-[4-(3-benzenesulphonyl-5-methyl-methylsulphonyl-pyrazolo[1,5-a]pyrimidin-7-yl)-piperazin-1-yl]-ethanol as colourless crystals, m.p. 189-190°.

Example 103-Benzenesulphonyl-5-methyl-2-methylsulphanyl-7-(4-phenyl-piperazine-1-yl)-pyrazolo[1,5-a]pyrimidine

5 [0044] 0.16 g (1 mmol) of N-phenyl-piperazine was added to a solution of 0.17 g (0.5 mmol) of 3-benzenesulphonyl-7-chloro-5-methyl-2-methylsulphanyl-pyrazolo[1,5-a]pyrimidine in 3 ml of DMF and stirred at 60° for 2 hrs. The reaction solution was cooled to RT and evaporated in a high vacuum. The residue was partitioned between 2N NaOH and CH₂Cl₂. The aqueous phase was extracted three times with CH₂Cl₂, and the combined organic phases were dried (MgSO₄), filtered and evaporated. Subsequent chromatography (SiO₂, CH₂Cl₂/MeOH 19:1) and crystallization from EtOH yielded 0.16 g (67%) of 3-benzenesulphonyl-5-methyl-2-methylsulphanyl-7-(4-phenyl-piperazin-1-yl)-pyrazolo[1,5-a]pyrimidine as colourless crystals, m.p. > 230°.

Example 11

15 N-(3-Benzenesulphonyl-5-methyl-2-methylsulphanyl-pyrazolo[1,5-a]pyrimidin-7-yl)-N',N'-dimethyl-ethane-1,2-diamine

[0045] 0.088 g (1 mmol) of 2-dimethylaminoethylamine was added to a solution of 0.17 g (0.5 mmol) of 3-benzenesulphonyl-7-chloro-5-methyl-2-methylsulphanyl-pyrazolo[1,5-a]pyrimidine in 3 ml of DMF and stirred at 60° for 2 hrs. The reaction solution was cooled to RT and evaporated in a high vacuum. The residue was partitioned between 2N NaOH and CH₂Cl₂. The aqueous phase was extracted three times with CH₂Cl₂, and the combined organic phases were dried (MgSO₄), filtered and evaporated. Subsequent chromatography (SiO₂, CH₂Cl₂/MeOH 19:1) and crystallization from EtOH yielded 0.23 g (73%) of N-(3-benzenesulphonyl-5-methyl-2-methylsulphanyl-pyrazolo[1,5-a]pyrimidin-7-yl)-N',N'-dimethyl-ethane-1,2-diamine as colourless crystals, m.p. 190-191°.

Example 12(3R,5S)-3-Benzenesulphonyl-7-(3,5-dimethyl-piperazin-1-yl)-5-methyl-2-methylsulphanyl-pyrazolo[1,5-a]pyrimidine

30 [0046] 0.28 g (2 mmol) of cis-2,6-dimethylpiperazine was added to a solution of 0.35 g (1 mmol) of 3-benzenesulphonyl-7-chloro-5-methyl-2-methylsulphanyl-pyrazolo[1,5-a]pyrimidine in 5 ml of DMF and stirred at 60° for 2 hrs. The reaction solution was cooled to RT and evaporated in a high vacuum. The residue was partitioned between 2N NaOH and CH₂Cl₂. The aqueous phase was extracted three times with CH₂Cl₂, and the combined organic phases were dried (MgSO₄), filtered and evaporated. Subsequent chromatography (SiO₂, CH₂Cl₂/MeOH 19:1) and crystallization from EtOH yielded 0.29 g (67%) of (3R,5S)-3-benzenesulphonyl-7-(3,5-dimethyl-piperazin-1-yl)-5-methyl-2-methylsulphanyl-pyrazolo[1,5-a]pyrimidine as colourless crystals, m.p. 220-221°.

Example 13

40 3-Benzenesulphonyl-5-methyl-2-methylsulphanyl-7-piperazin-1-yl-pyrazolo[1,5-a]pyrimidine

[0047]

45 a) A solution of 7.08 g (25 mmol) of 5-methylsulphanyl-4-(toluene-4-sulphonyl)-2H-pyrazol-3-ylamine and 4.0 ml (31.25 mmol) of ethyl acetoacetate in 30 l of acetic acid was heated at reflux for 1.5 hrs. The reaction solution was cooled to 0° and stirred at this temperature for 30 min. The separated crystals were filtered off under suction and dried at 50°/10 Torr. There were thus obtained 7.20 g (82%) of 5-methyl-2-methylsulphanyl-3-(toluene-4-sulphonyl)-pyrazolo[1,5-a]pyrimidin-7-ol as white crystals, m.p. > 230°.

50 b) A suspension of 3.8 g (10.8 mmol) of 5-methyl-2-methylsulphanyl-3-(toluene-4-sulphonyl)-pyrazolo[1,5-a]pyrimidin-7-ol in 20 l of POCl₃ was heated at reflux for 1 hr. The reaction solution was cooled to RT and evaporated. The residue was treated with 100 ml of ice-water and the pH value of the solution was adjusted to 8 with sat. NaHCO₃ solution. The aqueous phase was extracted three times with CH₂Cl₂, and the organic phases were dried (MgSO₄), filtered and evaporated. Chromatography (SiO₂, CH₂Cl₂/AcOEt 25:1) of the residue yielded 3.8 g (95%) of 7-chloro-5-methyl-2-methylsulphanyl-3-(toluene-4-sulphonyl)-pyrazolo[1,5-a]pyrimidine as pale yellow crystals, m.p. 197-198°.

c) 0.3 g (3.4 mmol) of piperazine in 10 ml of DMF was added to a solution of 0.62 g (1.7 mmol) of 7-chloro-5-methyl-

2-methyl-sulphanyl-3-(toluene-4-sulphonyl)-pyrazolo[1,5-a]pyrimidine in 10 ml of DMF and stirred at 60° for 2 hrs. The reaction solution was cooled to RT and evaporated in a high vacuum. The residue was partitioned between 2N NaOH and CH₂Cl₂. The aqueous phase was extracted three times with CH₂Cl₂, and the combined organic phases were dried (MgSO₄), filtered and evaporated. Subsequent chromatography (SiO₂, CH₂Cl₂/MeOH 6:1) and crystallization from EtOH yielded 0.30 g (42%) of 3-benzenesulphonyl-5-methyl-2-methylsulphanyl-7-piperazin-1-yl-pyrazolo[1,5-a]pyrimidine as colourless crystals, m.p. 137-139°.

Example 14**5-Methyl-7-(4-methyl-piperazin-1-yl)-2-methylsulphanyl-3-(toluene-4-sulphonyl)-pyrazolo[1,5-a]pyrimidine**

[0048] In an analogous manner to that described in Example 2, from 7-chloro-5-methyl-2-methylsulphanyl-3-(toluene-4-sulphonyl)-pyrazolo[1,5-a]pyrimidine and 1-methyl-piperazine there was obtained 5-methyl-7-(4-methyl-piperazin-1-yl)-2-methylsulphanyl-3-(toluene-4-sulphonyl)-pyrazolo[1,5-a]pyrimidine as colourless crystals, m.p. 221-223°.

Example 15**Methyl-[5-methyl-2-methylsulphanyl-3-(toluene-4-sulphonyl)-pyrazolo[1,5-a]pyrimidin-7-yl]-amine**

[0049] In an analogous manner to that described in Example 3, from 7-chloro-5-methyl-2-methylsulphanyl-3-(toluene-4-sulphonyl)-pyrazolo[1,5-a]pyrimidine and methylamine in EtOH there was obtained methyl-[5-methyl-2-methylsulphanyl-3-(toluene-4-sulphonyl)-pyrazolo[1,5-a]pyrimidin-7-yl]-amine as colourless crystals, m.p. > 230°.

Example 16**5-Methyl-2-methylsulphanyl-3-(toluene-4-sulphonyl)-pyrazolo[1,5-a]pyrimidin-7-ylamine**

[0050] In an analogous manner to that described in Example 4, from 7-chloro-5-methyl-2-methylsulphanyl-3-(toluene-4-sulphonyl)-pyrazolo[1,5-a]pyrimidine and NH₃ in MeOH there was obtained 5-methyl-2-methylsulphanyl-3-(toluene-4-sulphonyl)-pyrazolo[1,5-a]pyrimidin-7-ylamine as colourless crystals, m.p. > 230°.

Example 17**Dimethyl-[5-methyl-2-methylsulphanyl-3-(toluene-4-sulphonyl)-pyrazolo[1,5-a]pyrimidin-7-yl]-amine**

[0051] In an analogous manner to that described in Example 5, from 7-chloro-5-methyl-2-methylsulphanyl-3-(toluene-4-sulphonyl)-pyrazolo[1,5-a]pyrimidine and dimethylamine in EtOH there was obtained dimethyl-[5-methyl-2-methylsulphanyl-3-(toluene-4-sulphonyl)-pyrazolo[1,5-a]pyrimidin-7-yl]-amine as colourless crystals, m.p. > 230°.

Example 18**3-(4-isopropyl-benzenesulphonyl)-5-methyl-2-methylsulphanyl-7-piperazin-1-yl-pyrazolo[1,5-a]pyrimidine****[0052]**

a) 1.8 g (44.6 mmol) of NaH (60% suspension in oil) were added portionwise to a solution of 5 g (22.3 mmol) of (4-isopropyl-benzenesulphonyl)-acetonitrile and 1.4 ml of CS₂ in 14 ml of DMSO and stirred at room temperature for 45 min. Subsequently, 2.9 ml (47 mmol) of methyl iodide were slowly added dropwise thereto and stirred at RT for 2 hrs. After the addition of 30 ml of H₂O the separated crystals were filtered off under suction and crystallized from EtOH/CH₂Cl₂. There were thus obtained 4.9 g (67%) of 2-(4-isopropyl-benzenesulphonyl)-3,3-bis-methylsulphanyl-acrylonitrile as pale yellow crystals, m.p. 87°.

b) 0.36 ml (7.3 ml) of NH₂NH₂ was added to a solution of 2.0 g (6.1 mmol) of 2-(4-isopropyl-benzenesulphonyl)-3,3-bis-methylsulphanyl-acrylonitrile in 11 ml of EtOH and heated at reflux for 30 min. The pale brown solution was evaporated and chromatographed (SiO₂, CH₂Cl₂/MeOH 9:1). There were thus obtained 1.82 g (69%) of 4-isopropyl-benzenesulphonyl)-5-methylsulphanyl-2H-pyrazol-3-ylamine as a beige foam.

c) A solution of 1.80 g (5.8 mmol) of 4-(4-isopropyl-benzenesulphonyl)-5-methylsulphanyl-2H-pyrazol-3-ylamine

and 1.13 ml (8.8 mmol) of ethyl acetoacetate in 10 ml of acetic acid was heated at reflux for 1.5 hrs. The reaction solution was cooled to 0° and stirred at this temperature for 30 min. The separated crystals were filtered off and dried at 50°/10 Torr. There were thus obtained 1.82 g (83%) of 3-(4-isopropyl-benzenesulphonyl)-5-methyl-2-methylsulphanyl-pyrazolo[1,5-a]pyrimidin-7-ol as white crystals, m.p. > 230°.

d) A suspension of 1.8 g (4.8 mmol) of 3-(4-isopropyl-benzenesulphonyl)-5-methyl-2-methylsulphanyl-pyrazolo[1,5-a]pyrimidin-7-ol in 30 ml of POCl₃ was heated at reflux for 45 min. The reaction solution was cooled to RT and evaporated. The residue was treated with 100 ml of ice-water and the pH value of the solution was adjusted to 8 with sat. NaHCO₃ solution. The aqueous phase was extracted three times with CH₂Cl₂, and the organic phases were dried (MgSO₄), filtered and evaporated. Chromatography (SiO₂, CH₂Cl₂/AcOEt 19:1) of the residue yielded 1.78 g (93%) of 3-(4-isopropyl-benzenesulphonyl)-5-methyl-2-methylsulphanyl-pyrazolo[1,5-a]pyrimidin-7-ol as pale yellow crystals, m.p. 183-184°.

e) In an analogous manner to that described in Example 1c), from 7-chloro-3-(4-isopropyl-benzenesulphonyl)-5-methyl-2-methylsulphanyl-pyrazolo[1,5-a]pyrimidine and piperazine there was obtained 3-(4-isopropyl-benzenesulphonyl)-5-methyl-2-methylsulphanyl-7-piperazin-1-yl-pyrazolo[1,5-a]pyrimidine as colourless crystals, m.p. > 230°.

Example 19

3-(4-Isopropyl-benzenesulphonyl)-5-methyl-7-(4-methyl-piperazin-1-yl)-2-methylsulphanyl-pyrazolo[1,5-a]pyrimidine

[0053] In an analogous manner to that described in Example 2, from 7-chloro-3-(4-isopropyl-benzenesulphonyl)-5-methyl-2-methylsulphanyl-pyrazolo[1,5-a]pyrimidine and 1-methyl-piperazine there was obtained 3-(4-isopropyl-benzenesulphonyl)-5-methyl-7-(4-methyl-piperazin-1-yl)-2-methylsulphanyl-pyrazolo[1,5-a]pyrimidine as colourless crystals, m.p. 218-219°.

Example 20

3-(4-Isopropyl-benzenesulphonyl)-5-methyl-7-(4-methyl-piperazin-1-yl)-2-methylsulphanyl-pyrazolo[1,5-a]pyrimidine

[0054] In an analogous manner to that described in Example 4, from 7-chloro-3-(4-isopropyl-benzenesulphonyl)-5-methyl-2-methylsulphanyl-pyrazolo[1,5-a]pyrimidine and NH₃ in MeOH there was obtained 3-(4-isopropyl-benzenesulphonyl)-5-methyl-7-(4-methyl-piperazin-1-yl)-2-methylsulphanyl-pyrazolo[1,5-a]pyrimidine as colourless crystals, m.p. > 230°.

Example 21

[3-(4-Isopropyl-benzenesulphonyl)-5-methyl-2-methylsulphanyl-pyrazolo[1,5-a]pyrimidin-7-yl]-dimethyl-amine

[0055] In an analogous manner to that described in Example 5, from 7-chloro-3-(4-isopropyl-benzenesulphonyl)-5-methyl-2-methylsulphanyl-pyrazolo[1,5-a]pyrimidine and dimethyl-amine in EtOH there was obtained [3-(4-isopropyl-benzenesulphonyl)-5-methyl-2-methylsulphanyl-pyrazolo[1,5-a]pyrimidin-7-yl]-dimethyl-amine as colourless crystals, m.p. 222-224°.

Example 22

3-(4-tert-Butyl-benzenesulphonyl)-5-methyl-2-methylsulphanyl-7-piperazin-1-yl-pyrazolo[1,5-a]pyrimidine

[0056]

a) In an analogous manner to that described in Example 18 a) to d), starting from (4-tert-butyl-benzenesulphonyl)-acetonitrile there was obtained 3-(4-tert-butyl-benzenesulphonyl)-7-chloro-5-methyl-2-methylsulphanyl-pyrazolo[1,5-a]pyrimidine as a beige foam.

b) In an analogous manner to that described in Example 1c), from 3-(4-tert-butyl-benzenesulphonyl)-7-chloro-5-methyl-2-methylsulphanyl-pyrazolo[1,5-a]pyrimidine and piperazine there was obtained 3-(4-tert-butyl-benzenesulphonyl)-5-methyl-2-methylsulphanyl-7-piperazin-1-yl-pyrazolo[1,5-a]pyrimidine as colourless crystals, m.p.

178-180°.

Example 23

3-(4-tert-Butyl-benzenesulphonyl)-5-methyl-7-(4-methyl-piperazin-1-yl)-2-methylsulphanyl-pyrazolo[1,5-a]pyrimidine

[0057] In an analogous manner to that described in Example 2, from 3-(4-tert-butyl-benzenesulphonyl)-7-chloro-5-methyl-2-methylsulphanyl-pyrazolo[1,5-a]pyrimidine and 1-methyl-piperazine there was obtained 3-(4-tert-butyl-benzenesulphonyl)-5-methyl-7-(4-methyl-piperazin-1-yl)-2-methylsulphanyl-pyrazolo[1,5-a]pyrimidine as colourless crystals, m.p. 238-239°.

Example 24

3-(4-tert-Butyl-benzenesulphonyl)-5-methyl-2-methylsulphanyl-pyrazolo[1,5-a]pyrimidin-7-ylamine

[0058] In an analogous manner to that described in Example 4, from 3-(4-tert-butyl-benzenesulphonyl)-7-chloro-5-methyl-2-methylsulphanyl-pyrazolo[1,5-a]pyrimidine and NH₃ in MeOH there was obtained 3-(4-tert-butyl-benzenesulphonyl)-5-methyl-2-methylsulphanyl-pyrazolo[1,5-a]pyrimidin-7-ylamine as colourless crystals, m.p. > 230°.

Example 25

3-(4-Chloro-benzenesulphonyl)-5-methyl-2-methylsulphanyl-7-piperazin-1-yl-pyrazolo[1,5-a]pyrimidine

[0059]

(a) In an analogous manner to that described in Example 18 a) to d), starting from (4-chloro-benzenesulphonyl)-acetonitrile there was obtained 7-chloro-3-(4-chloro-benzenesulphonyl)-5-methyl-2-methylsulphanyl-pyrazolo[1,5-a]pyrimidine as a colourless foam.

(b) In an analogous manner to that described in Example 1c), from 7-chloro-3-(4-chlorobenzenesulphonyl)-5-methyl-2-methylsulphanyl-pyrazolo[1,5-a]pyrimidine and piperazine there was obtained 3-(4-chloro-benzenesulphonyl)-5-methyl-2-methylsulphanyl-7-piperazin-1-yl-pyrazolo[1,5-a]pyrimidine as colourless crystals, m.p. 214-217°.

Example 26

3-(4-Chloro-benzenesulphonyl)-5-methyl-7-(4-methyl-piperazin-1-yl)-2-methylsulphanyl-pyrazolo[1,5-a]pyrimidine

[0060] In an analogous manner to that described in Example 2, from 7-chloro-3-(4-chlorobenzenesulphonyl)-5-methyl-2-methylsulphanyl-pyrazolo[1,5-a]pyrimidine and 1-methyl-piperazine there was obtained 3-(4-chloro-benzenesulphonyl)-5-methyl-7-(4-methyl-piperazin-1-yl)-2-methylsulphanyl-pyrazolo[1,5-a]pyrimidine as colourless crystals, m.p. 200-201°.

Example 27

3-(4-Chloro-benzenesulphonyl)-5-methyl-2-methylsulphanyl-pyrazolo[1,5-a]pyrimidin-7-ylamine

[0061] In an analogous manner to that described in Example 4, from 7-chloro-3-(4-chloro-benzenesulphonyl)-5-methyl-2-methylsulphanyl-pyrazolo[1,5-a]pyrimidine and NH₃ in MeOH there was obtained 3-(4-chloro-benzenesulphonyl)-5-methyl-2-methylsulphanyl-pyrazolo[1,5-a]pyrimidin-7-ylamine as colourless crystals, m.p. >230°.

Example 28

[3-(4-Chloro-benzenesulphonyl)-5-methyl-2-methylsulphanyl-pyrazolo[1,5-a]pyrimidin-7-yl]-dimethyl-amine

[0062] In an analogous manner to that described in Example 5, from 7-chloro-3-(4-chloro-benzenesulphonyl)-5-methyl-2-methylsulphanyl-pyrazolo[1,5-a]pyrimidine and dimethyl-amine in EtOH there was obtained [3-(4-chloro-benzenesulphonyl)-5-methyl-2-methylsulphanyl-pyrazolo[1,5-a]pyrimidin-7-yl]-dimethyl-amine as colourless crystals, m.p. 221-223°.

Example 293-(2,4-Dichloro-benzenesulphonyl)-5-methyl-2-methylsulphanyl-7-piperazin-1-yl-pyrazolo[1,5-a]pyrimidine

5 [0063]

(a) In an analogous manner to that described in Example 18 a) to d), starting from (2,4-chloro-benzenesulphonyl)-acetonitrile there was obtained 7-chloro-3-(2,4-dichloro-benzenesulphonyl)-5-methyl-2-methylsulphanyl-pyrazolo[1,5-a]pyrimidine as a colourless foam.

10 (b) In an analogous manner to that described in Example 1c), from 7-chloro-3-(2,4-dichloro-benzenesulphonyl)-5-methyl-2-methylsulphanyl-pyrazolo[1,5-a]pyrimidine and piperazine there was obtained 3-(2,4-dichloro-benzenesulphonyl)-5-methyl-2-methylsulphanyl-7-piperazin-1-yl-pyrazolo[1,5-a]pyrimidine as colourless crystals, m.p. >230°.

15

Example 303-(2,4-Chloro-benzenesulphonyl)-5-methyl-7-(4-methyl-piperazin-1-yl)-2-methylsulphanyl-pyrazolo[1,5-a]pyrimidine

20 [0064] In an analogous manner to that described in Example 2, from 7-chloro-3-(2,4-dichloro-benzenesulphonyl)-5-methyl-2-methylsulphanyl-pyrazolo[1,5-a]pyrimidine and 1-methyl-piperazine there was obtained 3-(2,4-chloro-benzenesulphonyl)-5-methyl-7-(4-methyl-piperazin-1-yl)-2-methylsulphanyl-pyrazolo[1,5-a]pyrimidine as colourless crystals, m.p. >230°.

25 **Example 31**3-(2,4-Chloro-benzenesulphonyl)-5-methyl-2-methylsulphanyl-pyrazolo[1,5-a]pyrimidin-7-ylamine

30 [0065] In an analogous manner to that described in Example 4, from 7-chloro-3-(2,4-chloro-benzenesulphonyl)-5-methyl-2-methylsulphanyl-pyrazolo[1,5-a]pyrimidine and NH₃ in MeOH there was obtained 3-(2,4-chloro-benzenesulphonyl)-5-methyl-2-methylsulphanyl-pyrazolo[1,5-a]pyrimidin-7-ylamine as colourless crystals, m.p. >230°.

Example 3235 3-(4-Bromo-benzenesulphonyl)-5-methyl-2-methylsulphanyl-7-piperazin-1-yl-pyrazolo[1,5-a]pyrimidine

[0066]

40 (a) In an analogous manner to that described in Example 18 a) to d), starting from (4-bromo-benzenesulphonyl)-acetonitrile there was obtained 3-(4-bromo-benzenesulphonyl)-7-chloro-5-methyl-2-methylsulphanyl-pyrazolo[1,5-a]pyrimidine as a colourless foam.

45 (b) In an analogous manner to that described in Example 1c), from 3-(4-bromo-benzenesulphonyl)-7-chloro-5-methyl-2-methylsulphanyl-pyrazolo[1,5-a]pyrimidine and piperazine there was obtained 3-(4-bromo-benzenesulphonyl)-5-methyl-2-methylsulphanyl-7-piperazin-1-yl-pyrazolo[1,5-a]pyrimidine as colourless crystals, m.p. 212-214°.

Example 3350 3-(4-Bromo-benzenesulphonyl)-5-methyl-7-(4-methyl-piperazin-1-yl)-2-methylsulphanyl-pyrazolo[1,5-a]pyrimidine

[0067] In an analogous manner to that described in Example 2, from 3-(4-bromo-benzenesulphonyl)-7-chloro-5-methyl-2-methylsulphanyl-pyrazolo[1,5-a]pyrimidine and 1-methyl-piperazine there was obtained 3-(4-bromo-benzenesulphonyl)-5-methyl-7-(4-methyl-piperazin-1-yl)-2-methylsulphanyl-pyrazolo[1,5-a]pyrimidine as colourless crystals, m.p. 202-203°.

55

Exempl 343-(4-Bromo-benzenesulphonyl)-5-methyl-2-methylsulphanyl-pyrazolo[1,5-a]pyrimidin-7-ylamine

- 5 **[0068]** In an analogous manner to that described in Example 4, from 3-(4-bromo-benzenesulphonyl)-7-chloro-5-methyl-2-methylsulphanyl-pyrazolo[1,5-a]pyrimidine and NH_3 in MeOH there was obtained 3-(4-bromo-benzenesulphonyl)-5-methyl-2-methylsulphanyl-pyrazolo[1,5-a]pyrimidin-7-ylamine as colourless crystals, m.p. $>230^\circ$.

Example 35

10

3-(4-Methoxy-benzenesulphonyl)-5-methyl-2-methylsulphanyl-7-piperazin-1-yl-pyrazolo[1,5-a]pyrimidine**[0069]**

- 15 (a) In an analogous manner to that described in Example 18 a) to d), starting from (4-methoxy-benzenesulphonyl)-acetonitrile there was obtained 7-chloro-3-(4-methoxybenzenesulphonyl)-5-methyl-2-methylsulphanyl-pyrazolo[1,5-a]pyrimidine as a colourless foam.

- 20 (b) In an analogous manner to that described in Example 1c), from 7-chloro-3-(4-methoxy-benzenesulphonyl)-5-methyl-2-methylsulphanyl-pyrazolo[1,5-a]pyrimidine and piperazine there was obtained 3-(4-methoxy-benzenesulphonyl)-5-methyl-2-methylsulphanyl-7-piperazin-1-yl-pyrazolo[1,5-a]pyrimidine as colourless crystals, m.p. $176-177^\circ$.

Example 36

25

3-(4-Methoxy-benzenesulphonyl)-5-methyl-7-(4-methyl-piperazin-1-yl)-2-methylsulphanyl-pyrazolo[1,5-a]pyrimidine

- 30 **[0070]** In an analogous manner to that described in Example 2, from 7-chloro-3-(4-methoxy-benzenesulphonyl)-5-methyl-2-methylsulphanyl-pyrazolo[1,5-a]pyrimidine and 1-methyl-piperazine there was obtained 3-(4-methoxy-benzenesulphonyl)-5-methyl-7-(4-methyl-piperazin-1-yl)-2-methylsulphanyl-pyrazolo[1,5-a]pyrimidine as colourless crystals, m.p. $212-213^\circ$.

Example 37

35

3-(4-Methoxy-benzenesulphonyl)-5-methyl-2-methylsulphanyl-pyrazolo[1,5-a]pyrimidin-7-ylamine

- 40 **[0071]** In an analogous manner to that described in Example 4, from 7-chloro-3-(4-methoxy-benzenesulphonyl)-5-methyl-2-methylsulphanyl-pyrazolo[1,5-a]pyrimidine and NH_3 in MeOH there was obtained 3-(4-methoxy-benzenesulphonyl)-5-methyl-2-methylsulphanyl-pyrazolo[1,5-a]pyrimidin-7-ylamine as colourless crystals, m.p. $>230^\circ$.

Example 385-Methyl-7-(4-methyl-piperazin-1-yl)-2-methylsulphanyl-3-(naphthalene-2-sulphonyl)-pyrazolo[1,5-a]pyrimidine

45

[0072]

- 50 (a) In an analogous manner to that described in Example 18 a) to d), starting from (naphthalene-2-sulphonyl)-acetonitrile there was obtained 7-chloro-5-methyl-2-methylsulphanyl-3-(naphthalene-2-sulphonyl)-pyrazolo[1,5-a]pyrimidine as a colourless foam.

- 55 (b) In an analogous manner to that described in Example 2), from 7-chloro-5-methyl-2-methylsulphanyl-3-(naphthalene-2-sulphonyl)-pyrazolo[1,5-a]pyrimidine and 1-methyl-piperazine there was obtained 5-methyl-7-(4-methyl-piperazin-1-yl)-2-methylsulphanyl-3-(naphthalene-2-sulphonyl)-pyrazolo[1,5-a]pyrimidine as colourless crystals, m.p. $> 230^\circ$

Example 39

Dimethyl-[5-methyl-2-methylsulphanyl-3-(naphthalene-2-sulphonyl)-pyrazolo[1,5-a]pyrimidin-7-yl]-amine

- 5 **[0073]** In an analogous manner to that described in Example 6, from 7-chloro-5-methyl-2-methylsulphanyl-3-(naphthalene-2-sulphonyl)-pyrazolo[1,5-a]pyrimidine and dimethyl-amine in EtOH there was obtained dimethyl-[5-methyl-2-methylsulphanyl-3-(naphthalene-2-sulphonyl)-pyrazolo[1,5-a]pyrimidin-7-yl]-amine as colourless crystals, m.p. >230°.

10 **Example 40**

5-Methyl-2-methylsulphanyl-3-(naphthalene-2-sulphonyl)-pyrazolo[1,5-a]pyrimidine-7-ylamine

- 15 **[0074]** In an analogous manner to that described in Example 4, from 7-chloro-5-methyl-2-methylsulphanyl-3-(naphthalene-2-sulphonyl)-pyrazolo[1,5-a]pyrimidine and NH₃ in MeOH there was obtained 5-methyl-2-methylsulphanyl-3-(naphthalene-2-sulphonyl)-pyrazolo[1,5-a]pyrimidine-7-ylamine as colourless crystals, m.p. >230°.

Example 41

20 3-(4-Fluoro-benzenesulphonyl)-5-methyl-2-methylsulphanyl-7-piperazin-1-yl-pyrazolo[1,5-a]pyrimidine

[0075]

- 25 (a) In an analogous manner to that described in Example 18 a) to d), starting from (4-fluoro-benzenesulphonyl)-acetonitrile there was obtained 7-chloro-3-(4-fluoro-benzenesulphonyl)-5-methyl-2-methylsulphanyl-pyrazolo[1,5-a]pyrimidine as a colourless foam.

- 30 (b) In an analogous manner to that described in Example 1c), from 7-chloro-3-(4-fluoro-benzenesulphonyl)-5-methyl-2-methylsulphanyl-pyrazolo[1,5-a]pyrimidine and piperazine there was obtained 3-(4-fluoro-benzenesulphonyl)-5-methyl-2-methylsulphanyl-7-piperazin-1-yl-pyrazolo[1,5-a]pyrimidine as colourless crystals, m.p. 180-181°.

Example 42

35 3-(4-Fluoro-benzenesulphonyl)-5-methyl-7-(4-methyl-piperazin-1-yl)-2-methylsulphanyl-pyrazolo[1,5-a]pyrimidine

- [0076]** In an analogous manner to that described in Example 2, from 7-chloro-3-(4-fluorobenzenesulphonyl)-5-methyl-2-methylsulphanyl-pyrazolo[1,5-a]pyrimidine and 1-methyl-piperazine there was obtained 3-(4-fluoro-benzenesulphonyl)-5-methyl-7-(4-methyl-piperazin-1-yl)-2-methylsulphanyl-pyrazolo[1,5-a]pyrimidine as colourless crystals, m.p. 197-198°.

40

Example 43

3-(4-Fluoro-benzenesulphonyl)-5-methyl-2-methylsulphanyl-pyrazolo[1,5-a]pyrimidin-7-ylamine

- 45 **[0077]** In an analogous manner to that described in Example 4, from 7-chloro-3-(4-fluoro-benzenesulphonyl)-5-methyl-2-methylsulphanyl-pyrazolo[1,5-a]pyrimidine and NH₃ in MeOH there was obtained 3-(4-fluoro-benzenesulphonyl)-5-methyl-2-methylsulphanyl-pyrazolo[1,5-a]pyrimidin-7-ylamine as colourless crystals, m.p. >230°.

Example 44

50

3-(4-Iodo-benzenesulphonyl)-5-methyl-2-methylsulphanyl-pyrazolo[1,5-a]pyrimidine-7-ylamine

[0078]

- 55 (a) In an analogous manner to that described in Example 18 a) to d), starting from (4-iodo-benzenesulphonyl)-acetonitrile there was obtained 7-chloro-3-(4-iodo-benzenesulphonyl)-5-methyl-2-methylsulphanyl-pyrazolo[1,5-a]pyrimidine as a colourless foam.

(b) In an analogous manner to that described in Example 4), from 7-chloro-3-(4-iodo-benzenesulphonyl)-5-methyl-2-methylsulphanyl-pyrazolo[1,5-a]pyrimidine and NH_3 in MeOH there was obtained 3-(4-iodo-benzenesulphonyl)-5-methyl-2-methylsulphanyl-pyrazolo[1,5-a]pyrimidine-7-ylamine as colourless crystals, m.p. $>230^\circ$.

5 **Exempl 45**

3-Benzenesulphonyl-5,6-dimethyl-2-methylsulphanyl-7-piperazin-1-yl-pyrazolo[1,5-a]pyrimidine

[0079]

10

(a) In an analogous manner to that described in Example 1a, b), from 4-benzenesulphonyl-5-methylsulphanyl-2H-pyrazol-3-ylamine and ethyl 2-methyl-acetoacetate there was obtained 3-benzenesulphonyl-7-chloro-5,6-dimethyl-2-methylsulphanyl-pyrazolo[1,5-a]pyrimidine as a colourless foam.

15

(b) In an analogous manner to that described in Example 1c), from 3-benzenesulphonyl-7-chloro-5,6-dimethyl-2-methylsulphanyl-pyrazolo[1,5-a]pyrimidine and piperazine there was obtained 3-benzenesulphonyl-5,6-dimethyl-2-methylsulphanyl-7-piperazin-1-yl-pyrazolo[1,5-a]pyrimidine as colourless crystals, m.p. $159-160^\circ$.

Example 46

20

3-Benzenesulphonyl-5,6-dimethyl-7-(4-methyl-piperazin-1-yl)-2-methylsulphanylpyrazolo[1,5-a]pyrimidine

25

[0080] In an analogous manner to that described in Example 1c), from 3-benzenesulphonyl-7-chloro-5,6-dimethyl-2-methylsulphanyl-pyrazolo[1,5-a]pyrimidine and 1-methyl-piperazine there was obtained 3-benzenesulphonyl-5,6-dimethyl-7-(4-methyl-piperazin-1-yl)-2-methylsulphanyl-pyrazolo[1,5-a]pyrimidine as colourless crystals, m.p. $183-185^\circ$.

Example 47

30

3-Benzenesulphonyl-2-methylsulphanyl-7-piperazin-1-yl-5-propyl-pyrazolo[1,5-a]pyrimidine

[0081]

35

(a) In an analogous manner to that described in Example 1a, b), from 4-benzenesulphonyl-5-methylsulphanyl-2H-pyrazol-3-ylamine and ethyl butyrylacetate there was obtained 3-benzenesulphonyl-7-chloro-2-methylsulphanyl-5-propyl-pyrazolo[1,5-a]pyrimidine as a colourless foam.

40

(b) In an analogous manner to that described in Example 1c), from 3-benzene-sulphonyl-7-chloro-2-methylsulphanyl-5-propyl-pyrazolo[1,5-a]pyrimidine and piperazine there was obtained 3-benzenesulphonyl-2-methylsulphanyl-7-piperazin-1-yl-5-propyl-pyrazolo[1,5-a]pyrimidine as colourless crystals, m.p. $197-199^\circ$.

Example 48

45

3-Benzenesulphonyl-7-(4-methyl-piperazin-1-yl)-2-methylsulphanyl-5-propyl-pyrazolo[1,5-a]pyrimidine

[0082] In an analogous manner to that described in Example 2, from 3-benzenesulphonyl-7-chloro-2-methylsulphanyl-5-propyl-pyrazolo[1,5-a]pyrimidine and 1-methyl-piperazine there was obtained 3-benzenesulphonyl-7-(4-methyl-piperazin-1-yl)-2-methylsulphanyl-5-propyl-pyrazolo[1,5-a]pyrimidine as colourless crystals, m.p. $207-209^\circ$.

50

Example 49

3-Benzenesulphonyl-5-cyclopropyl-2-methylsulphanyl-7-piperazin-1-yl-pyrazolo[1,5-a]pyrimidine

[0083]

55

a) In an analogous manner to that described in Example 1a, b), from 4-benzenesulphonyl-5-methylsulphanyl-2H-pyrazol-3-ylamine and ethyl 3-cyclopropyl-3-oxo-propionate there was obtained 3-benzenesulphonyl-7-chloro-5-cyclopropyl-2-methylsulphanyl-pyrazolo[1,5-a]pyrimidine as a colourless foam.

b) In an analogous manner to that described in Example 1c), from 3-benzenesulphonyl-7-chloro-5-cyclopropyl-2-methylsulphanyl-pyrazolo[1,5-a]pyrimidine and piperazine there was obtained 3-benzenesulphonyl-5-cyclopropyl-2-methylsulphanyl-7-piperazin-1-yl-pyrazolo[1,5-a]pyrimidine as colourless crystals, m.p. 214-215°.

Example 50

3-Benzenesulphonyl-5-cyclopropyl-2-methylsulphanyl-7(4-methylpiperazin-1-yl)-pyrazolo[1,5-a]pyrimidine

[0084] In an analogous manner to that described in Example 2, from 3-benzenesulphonyl-7-chloro-5-cyclopropyl-2-methylsulphanyl-pyrazolo[1,5-a]pyrimidine and 1-methyl-piperazine there was obtained 3-benzenesulphonyl-5-cyclopropyl-2-methylsulphanyl-7(4-methylpiperazin-1-yl)-pyrazolo[1,5-a]pyrimidine as colourless crystals, m.p. 162-164°.

Example 51

3-Benzenesulphonyl-5-cyclopropyl-2-methylsulphanyl-pyrazolo[1,5-a]pyrimidine-7-ylamine

[0085] In an analogous manner to that described in Example 4, from 3-benzenesulphonyl-7-chloro-5-cyclopropyl-2-methylsulphanyl-pyrazolo[1,5-a]pyrimidine and NH_3 in MeOH there was obtained 3-benzenesulphonyl-5-cyclopropyl-2-methylsulphanyl-pyrazolo[1,5-a]pyrimidine-7-ylamine as colourless crystals, m.p. > 230°.

Example 52

3-Benzenesulphonyl-2-methylsulphanyl-8-piperazin-1-yl-6,7-dihydro-5H-cyclopenta[d]pyrazolo[1,5-a]pyrimidine

[0086]

a) In an analogous manner to that described in Example 1a, b), from 4-benzenesulphonyl-5-methylsulphanyl-2H-pyrazol-3-ylamine and ethyl cyclopentanone-2-carboxylate there was obtained 3-benzenesulphonyl-8-chloro-2-methylsulphanyl-6,7-dihydro-5H-cyclopenta[d]pyrazolo[1,5-a]pyrimidine as a colourless foam.

b) In an analogous manner to that described in Example 1c), from 3-benzenesulphonyl-8-chloro-2-methylsulphanyl-6,7-dihydro-5H-cyclopenta[d]pyrazolo[1,5-a]pyrimidine and piperazine there was obtained 3-benzenesulphonyl-2-methylsulphanyl-8-piperazin-1-yl-6,7-dihydro-5H-cyclopenta[d]pyrazolo[1,5-a]pyrimidine as colourless crystals, m.p. 221-222.5°.

Example 53

3-Benzenesulphonyl-8-(4-methyl-piperazin-1-yl)-2-methylsulphanyl-6,7-dihydro-5H-cyclopenta[d]pyrazolo[1,5-a]pyrimidine

[0087] In an analogous manner to that described in Example 2, from 3-benzenesulphonyl-8-chloro-2-methylsulphanyl-6,7-dihydro-5H-cyclopenta[d]pyrazolo[1,5-a]pyrimidine and 1-methyl-piperazine there was obtained 3-benzenesulphonyl-8-(4-methyl-piperazin-1-yl)-2-methylsulphanyl-6,7-dihydro-5H-cyclopenta[d]pyrazolo[1,5-a]pyrimidine as colourless crystals, m.p. 228-229.5°.

Example 54

3-Benzenesulphonyl-2-methylsulphanyl-6,7-dihydro-5H-cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-ylamine

[0088] In an analogous manner to that described in Example 4, from 3-benzenesulphonyl-8-chloro-2-methylsulphanyl-6,7-dihydro-5H-cyclopenta[d]pyrazolo[1,5-a]pyrimidine and NH_3 in MeOH there was obtained 3-benzenesulphonyl-2-methylsulphanyl-6,7-dihydro-5H-cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-ylamine as colourless crystals, m.p. >230°.

Example 553-Benzenesulphonyl-2-methylsulphonyl-9-piperazin-1-yl-5,6,7,8-tetrahydro-pyrazolo[5,1-b]quinazoline

[0089]

a) In an analogous manner to that described in Example 1a, b), from 4-benzenesulphonyl-5-methylsulphonyl-2H-pyrazol-3-ylamine and ethyl cyclohexanone-2-carboxylate there was obtained 3-benzenesulphonyl-9-chloro-2-methylsulphonyl-5,6,7,8-tetrahydropyrazolo[5,1-b]quinazoline as a colourless foam.

b) In an analogous manner to that described in Example 1c), from 3-benzenesulphonyl-9-chloro-2-methylsulphonyl-5,6,7,8-tetrahydro-pyrazolo[5,1-b]quinazoline and piperazine there was obtained 3-benzenesulphonyl-2-methylsulphonyl-9-piperazin-1-yl-5,6,7,8-tetrahydro-pyrazolo[5,1-b]quinazoline as colourless crystals, m.p. 121-123°.

Example 563-Benzenesulphonyl-9-(4-methyl-piperazin-1-yl)-2-methylsulphonyl-5,6,7,8-tetrahydropyrazolo[5,1-b]quinazoline

[0090] In an analogous manner to that described in Example 2, from 3-benzenesulphonyl-9-chloro-2-methylsulphonyl-5,6,7,8-tetrahydro-pyrazolo[5,1-b]quinazoline and 1-methyl-piperazine there was obtained 3-benzenesulphonyl-9-(4-methyl-piperazin-1-yl)-2-methylsulphonyl-5,6,7,8-tetrahydro-pyrazolo[5,1-b]quinazoline as colourless crystals, m.p. 198-200°.

Example 573-Benzenesulphonyl-2-methylsulphonyl-8-piperazin-1-yl-5H,7H-pyrazolo[1,5-a]thieno[3,4-d]pyrimidine

[0091]

a) In an analogous manner to that described in Example 1a, b), from 4-benzenesulphonyl-5-methylsulphonyl-2H-pyrazol-3-ylamine and methyl 4-oxo-tetrahydro-thiophene-3-carboxylate there was obtained 3-benzenesulphonyl-8-chloro-2-methylsulphonyl-5H,7H-pyrazolo[1,5-a]thieno[3,4-d]pyrimidine as a colourless foam.

b) In an analogous manner to that described in Example 1c), from 3-benzenesulphonyl-8-chloro-2-methylsulphonyl-5H,7H-pyrazolo[1,5-a]thieno[3,4-d]pyrimidine and piperazine there was obtained 3-benzenesulphonyl-2-methylsulphonyl-8-piperazin-1-yl-5H,7H-pyrazolo[1,5-a]thieno[3,4-d]pyrimidine as colourless crystals, m.p. >230°.

Example 583-Benzenesulphonyl-8-(4-methyl-piperazin-1-yl)-2-methylsulphonyl-5H,7H-pyrazolo[1,5-a]thieno[3,4-d]pyrimidine

[0092] In an analogous manner to that described in Example 2, from 3-benzenesulphonyl-8-chloro-2-methylsulphonyl-5H,7H-pyrazolo[1,5-a]thieno[3,4-d]pyrimidine and 1-methyl-piperazine there was obtained 3-benzenesulphonyl-8-(4-methyl-piperazin-1-yl)-2-methylsulphonyl-5H,7H-pyrazolo[1,5-a]thieno[3,4-d]pyrimidine as colourless crystals, m.p. >230°.

Example 595-Methyl-2-methylsulphonyl-7-piperazin-1-yl-3-(thiophene-2-sulphonyl)-pyrazolo[1,5-a]pyrimidine

[0093]

a) In an analogous manner to that described in Example 18 a) to d), starting from thien-2-ylsulphonylacetonitrile there was obtained 7-chloro-5-methyl-2-methylsulphonyl-3-(thiophene-2-sulphonyl)-pyrazolo[1,5-a]pyrimidine as a colourless solid.

b) In an analogous manner to that described in Example 1c), from 7-chloro-5-methyl-2-methylsulphonyl-3-(thiophene-2-sulphonyl)-pyrazolo[1,5-a]pyrimidine and piperazine there was obtained 5-methyl-2-methylsulphonyl-

7-piperazin-1-yl-3-(thiophen-2-sulphonyl)-pyrazolo[1,5-a]pyrimidine as colourless crystals, m.p. 229-230°.

Exempl 60

5-Methyl-7-(4-methyl-piperazin-1-yl)-2-methylsulphanyl-3-(thiophene-2-sulphonyl)-pyrazolo[1,5-a]pyrimidine

[0094] In an analogous manner to that described in Example 2, from 7-chloro-5-methyl-2-methylsulphanyl-3-(thiophene-2-sulphonyl)-pyrazolo[1,5-a]pyrimidine and 1-methyl-piperazine there was obtained 5-methyl-7-(4-methyl-piperazin-1-yl)-2-methylsulphanyl-3-(thiophene-2-sulphonyl)-pyrazolo[1,5-a]pyrimidine as colourless crystals, m.p. >230°.

Example 61

5-Methyl-2-methylsulphanyl-3-(thiophene-2-sulphonyl)-pyrazolo[1,5-a]pyrimidin-7-ylamine

[0095] In an analogous manner to that described in Example 4, from 7-chloro-5-methyl-2-methylsulphanyl-3-(thiophene-2-sulphonyl)-pyrazolo[1,5-a]pyrimidine and NH_3 in MeOH there was obtained 5-methyl-2-methylsulphanyl-3-(thiophene-2-sulphonyl)-pyrazolo[1,5-a]pyrimidin-7-ylamine as colourless crystals, m.p. >230°.

Example 62

3-Benzenesulphonyl-5-isopropyl-7-(4-methyl-piperazin-1-yl)-2-methylsulphanyl-pyrazolo[1,5-a]pyrimidine

[0096]

a) In an analogous manner to that described in Example 1a, b), from 4-benzenesulphonyl-5-methylsulphanyl-2H-pyrazol-3-ylamine and ethyl isobutyrylacetate there was obtained 3-benzenesulphonyl-7-chloro-5-isopropyl-2-methylsulphanyl-pyrazolo[1,5-a]pyrimidine as a colourless foam.

b) In an analogous manner to that described in Example 2), from 3-benzenesulphonyl-7-chloro-5-isopropyl-2-methylsulphanyl-pyrazolo[1,5-a]pyrimidine and 1-methyl-piperazine there was obtained 3-benzenesulphonyl-5-isopropyl-7-(4-methyl-piperazin-1-yl)-2-methylsulphanyl-pyrazolo[1,5-a]pyrimidine as colourless crystals, m.p. 212-214°.

Example 63

3-Benzenesulphonyl-5-isopropyl-2-methylsulphanyl-pyrazolo[1,5-a]pyrimidin-7-ylamine

[0097] In an analogous manner to that described in Example 4, from 3-benzenesulphonyl-7-chloro-5-isopropyl-2-methylsulphanyl-pyrazolo[1,5-a]pyrimidine and NH_3 in MeOH there was obtained 3-benzenesulphonyl-5-isopropyl-

(78%) g of 3-benzenesulphonyl-5-tert-butyl-7-chloro-2-methylsulphonyl-pyrazolo[1,5-a]pyrimidine as a pale yellow foam.

c) 0.67 g (7.7 mmol) of piperazine in 10 ml of DMF was added to a solution of 1.23 g (3.1 mmol) of 3-benzenesulphonyl-5-tert-butyl-7-chloro-2-methylsulphonyl-pyrazolo[1,5-a]pyrimidine in 10 ml of DMF and stirred at RT for 2 hrs. The reaction solution was evaporated and the residue was partitioned between 2N NaOH and CH₂Cl₂. The aqueous phase was extracted three times with CH₂Cl₂, and the combined organic phases were dried (MgSO₄), filtered and evaporated. Subsequent chromatography (SiO₂, CH₂Cl₂/MeOH 19:1) and crystallization from EtOH yielded 0.25 g (18%) of 3-benzenesulphonyl-5-tert-butyl-2-methylsulphonyl-7-piperazin-1-yl-pyrazolo[1,5-a]pyrimidine as colourless crystals, m.p. 236-237°.

Example 65

3-Benzenesulphonyl-2-ethyl-5-methyl-7-piperazin-1-yl-pyrazolo[1,5-a]pyrimidine

[0099]

a) 0.2 ml of glacial acetic acid was added to a suspension of 5.0 g (27.6 mmol) of phenylsulphonylacetonitrile in 17.6 ml (88.6 mmol) of triethyl orthopropionate and subsequently heated to 140°. The EtOH formed was distilled off continuously. After 1.5 hr. the mixture was cooled to RT and evaporated to dryness in a high vacuum. There were thus obtained 7.3 g (100%) of a mixture of (E)- and (Z)-2-benzenesulphonyl-3-ethoxy-pent-2-enenitrile as a colourless oil.

b) A solution of 5.2 g (19.6 mmol) of (E)- and (Z)-2-benzenesulphonyl-3-ethoxy-pent-2-enenitrile and 1.24 ml (25.5 mol) of NH₂NH₂ in 50 ml of EtOH was heated at reflux for 1 hr. The brown reaction solution was cooled to RT, evaporated and chromatographed (SiO₂, CH₂Cl₂/MeOH 19:1). There were thus obtained 2.9 g (59%) of 4-benzenesulphonyl-5-ethyl-2H-pyrazol-3-ylamine as a beige oil.

c) A solution of 2.9 g (11.5 mmol) of 4-benzenesulphonyl-5-ethyl-2H-pyrazol-3-ylamine and 1.8 ml (13.8 mmol) of ethyl acetoacetate in 10 ml of acetic acid was heated at reflux for 3 hrs. The reaction solution was cooled to RT and evaporated. The residue was partitioned between CH₂Cl₂ and H₂O and the aqueous phase was washed three times with 150 ml of CH₂Cl₂. The combined organic phases were dried (MgSO₄), filtered and evaporated. Crystallization from ethyl acetate yielded 2.6 g (71%) of 3-benzenesulphonyl-2-ethyl-5-methyl-pyrazolo[1,5-a]pyrimidin-7-ol as colourless crystals.

d) A suspension of 2.0 g (6.3 mmol) of 3-benzenesulphonyl-2-ethyl-5-methyl-pyrazolo[1,5-a]pyrimidin-7-ol in 30 ml of POCl₃ was heated at reflux for 45 min. The reaction solution was cooled to RT and evaporated. The residue was treated with 100 ml of ice-water and the pH value of the solution was adjusted to 8 with sat. NaHCO₃ solution. The aqueous phase was extracted three times with 100 ml of CH₂Cl₂, and the organic phases were dried (MgSO₄), filtered and evaporated. Chromatography (SiO₂, CH₂Cl₂/MeOH 49:1) of the residue yielded 2.0 g (94%) of 3-benzenesulphonyl-7-chloro-2-ethyl-5-methyl-pyrazolo[1,5-a]pyrimidine as colourless crystals.

e) 0.64 g (7.4 mmol) of piperazine in 10 ml of DMF was added to a solution of 1.0 g (3 mmol) of 3-benzenesulphonyl-7-chloro-2-ethyl-5-methyl-pyrazolo[1,5-a]pyrimidine in 10 ml of DMF and stirred at 60° for 2 hrs. The DMF was evaporated in a high vacuum, the residue was partitioned between 2N NaOH and CH₂Cl₂. The aqueous phase was extracted three times with 50 ml of CH₂Cl₂ and the combined organic were dried (MgSO₄), filtered and evaporated. Subsequent chromatography (SiO₂, CH₂Cl₂/MeOH 9:1) and crystallization from EtOH yielded 0.32 g (27%) of 3-benzenesulphonyl-2-ethyl-5-methyl-7-piperazin-1-yl-pyrazolo[1,5-a]pyrimidine as colourless crystals, m.p. 150-150.8°.

Example 66

3-Benzenesulphonyl-2-ethyl-5-methyl-7-(4-methyl-piperazin-1-yl)-pyrazolo[1,5-a]pyrimidine

[0100] In an analogous manner to that described in Example 2, from 3-benzenesulphonyl-7-chloro-2-ethyl-5-methyl-pyrazolo[1,5-a]pyrimidine and 1-methyl-piperazine there was obtained 3-benzenesulphonyl-2-ethyl-5-methyl-7-(4-methyl-piperazin-1-yl)-pyrazolo[1,5-a]pyrimidine as colourless crystals, m.p. 171-172°.

Example 67

N-(3-Benzenesulphonyl-2-ethyl-5-methyl-pyrazolo[1,5-a]pyrimidin-7-yl)-N',N'-dimethyl-ethane-1,2-diamine

[0101] In an analogous manner to that described in Example 11) from 3-benzenesulphonyl-7-chloro-2-ethyl-5-methyl-

pyrazolo[1,5-a]pyrimidine and 2-dimethylaminoethylamine there was obtained N-(3-benzenesulphonyl-2-ethyl-5-methyl-pyrazolo[1,5-a]pyrimidin-7-yl)-N',N'-dimethyl-ethane-1,2-diamine

Example 68

3-(4-Bromo-benzenesulphonyl)-2-ethyl-5-methyl-7-piperazin-1-yl-pyrazolo[1,5-a]pyrimidine

[0102]

a) In an analogous manner to that described in Example 64 a) to d), from (4-bromo-benzenesulphonyl)-acetonitrile there was obtained 3-(4-bromo-benzenesulphonyl)-7-chloro-2-ethyl-5-methyl-pyrazolo[1,5-a]pyrimidine as colourless crystals.

b) In an analogous manner to that described in Example 1c), from 3-(4-bromo-benzenesulphonyl)-7-chloro-2-ethyl-5-methyl-pyrazolo[1,5-a]pyrimidine and piperazine there was obtained 3-(4-bromo-benzenesulphonyl)-2-ethyl-5-methyl-7-piperazin-1-yl-pyrazolo[1,5-a]pyrimidine as colourless crystals, m.p. 196-197°.

Example 69

3-(4-Bromo-benzenesulphonyl)-2-ethyl-5-methyl-7-piperazin-1-yl-pyrazolo[1,5-a]pyrimidine

[0103] In an analogous manner to that described in Example 2, from 3-(4-bromo-benzenesulphonyl)-7-chloro-2-ethyl-5-methyl-pyrazolo[1,5-a]pyrimidine and 1-methyl-piperazine there was obtained 3-(4-bromo-benzenesulphonyl)-2-ethyl-5-methyl-7-piperazin-1-yl-pyrazolo[1,5-a]pyrimidine as colourless crystals, m.p. 215-216°.

Example 70

N-[3-(4-Bromo-benzenesulphonyl)-2-ethyl-5-methyl-pyrazolo[1,5-a]pyrimidin-7-yl]-N',N'-dimethyl-ethane-1,2-diamine

[0104] In an analogous manner to that described in Example 11, from 3-(4-bromo-benzenesulphonyl)-7-chloro-2-ethyl-5-methyl-pyrazolo[1,5-a]pyrimidine and 2-dimethylamino-ethylamine there was obtained N-[3-(4-bromo-benzenesulphonyl)-2-ethyl-5-methyl-pyrazolo[1,5-a]pyrimidin-7-yl]-N',N'-dimethyl-ethane-1,2-diamine as colourless crystals, m.p. 210-211°.

Example 71

2-Ethyl-3-(4-methoxy-benzenesulphonyl)-5-methyl-7-piperazin-1-yl-pyrazolo[1,5-a]pyrimidine

[0105]

a) In an analogous manner to that described in Example 69 a) to d), from (4-methoxy-benzenesulphonyl)-acetonitrile there was obtained 7-chloro-2-ethyl-3-(4-methoxy-benzenesulphonyl)-5-methyl-pyrazolo[1,5-a]pyrimidine as colourless crystals.

b) In an analogous manner to that described in Example 1c), from 7-chloro-2-ethyl-3-(4-methoxy-benzenesulphonyl)-5-methyl-pyrazolo[1,5-a]pyrimidine and piperazine there was obtained 2-ethyl-3-(4-methoxy-benzenesulphonyl)-5-methyl-7-piperazin-1-yl-pyrazolo[1,5-a]pyrimidine as colourless crystals, m.p. 196-197°.

Example 72

2-Ethyl-3-(4-methoxy-benzenesulphonyl)-5-methyl-7-(4-methyl-piperazin-1-yl)-pyrazolo[1,5-a]pyrimidine

[0106] In an analogous manner to that described in Example 2, from 7-chloro-2-ethyl-3-(4-methoxy-benzenesulphonyl)-5-methyl-pyrazolo[1,5-a]pyrimidine and 1-methyl-piperazine there was obtained 2-ethyl-3-(4-methoxy-benzenesulphonyl)-5-methyl-7-(4-methyl-piperazin-1-yl)-pyrazolo[1,5-a]pyrimidine as colourless crystals, m.p. 178-188°.

Example 73

2-Ethyl-3-(4-methoxy-benzenesulphonyl)-5-methyl-pyrazolo[1,5-a]pyrimidin-7-ylamine

[0107] In an analogous manner to that described in Example 4, from 7-chloro-2-ethyl-3-(4-methoxy-benzenesulphonyl)-5-methyl-pyrazolo[1,5-a]pyrimidine and NH_3 in MeOH there was obtained 2-ethyl-3-(4-methoxy-benzenesulphonyl)-5-methyl-pyrazolo[1,5-a]pyrimidin-7-ylamine as colourless crystals, m.p. 186-188°.

Example 74

(3R,5S)-7-(3,5-Dimethyl-piperazin-1-yl)-2-ethyl-3-(4-methoxy-benzenesulphonyl)-5-methyl-pyrazolo[1,5-a]pyrimidine

[0108] In an analogous manner to that described in Example 12, from 7-chloro-2-ethyl-3-(4-methoxy-benzenesulphonyl)-5-methyl-pyrazolo[1,5-a]pyrimidine and cis-2,6-dimethyl-piperazine there was obtained (3R,5S)-7-(3,5-dimethyl-piperazin-1-yl)-2-ethyl-3-(4-methoxy-benzenesulphonyl)-5-methyl-pyrazolo[1,5-a]pyrimidine as colourless crystals, m.p. 151-152°.

Example 75

3-Benzenesulphonyl-2-ethyl-8-piperazin-1-yl-6,7-dihydro-5H-cyclopenta[d]pyrazolo[1,5-a]pyrimidine

[0109]

a) In an analogous manner to that described in Example 69 c) d), from 4-benzenesulphonyl-5-ethyl-2H-pyrazol-3-ylamine and ethyl cyclopentanone-2-carboxylate there was obtained 3-benzenesulphonyl-8-chloro-2-ethyl-6,7-dihydro-5H-cyclopenta[d]pyrazolo[1,5-a]pyrimidine as a colourless foam.

b) In an analogous manner to that described in Example 1c), from 3-benzenesulphonyl-8-chloro-2-ethyl-6,7-dihydro-5H-cyclopenta[d]pyrazolo[1,5-a]pyrimidine and piperazine there was obtained 3-benzenesulphonyl-2-ethyl-8-piperazin-1-yl-6,7-dihydro-5H-cyclopenta[d]pyrazolo[1,5-a]pyrimidine as colourless crystals, m.p. 200-201°.

Example 76

3-Benzenesulphonyl-2-ethyl-8-(4-methyl-piperazin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrazolo[1,5-a]pyrimidine

[0110] In an analogous manner to that described in Example 2, from 3-benzenesulphonyl-8-chloro-2-ethyl-6,7-dihydro-5H-cyclopenta[d]pyrazolo[1,5-a]pyrimidine and 1-methyl-piperazine there was obtained 3-benzenesulphonyl-2-ethyl-8-(4-methyl-piperazin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrazolo[1,5-a]pyrimidine as colourless crystals, m.p. 235-236°.

Example 77

3-Benzenesulphonyl-2-ethyl-6,7-dihydro-5H-cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-ylamine

[0111] In an analogous manner to that described in Example 4, from 3-benzenesulphonyl-8-chloro-2-ethyl-6,7-dihydro-5H-cyclopenta[d]pyrazolo[1,5-a]pyrimidine and NH_3 in MeOH there was obtained 3-benzenesulphonyl-2-ethyl-6,7-dihydro-5H-cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-ylamine as colourless crystals, m.p. >230°.

Example 78

(3R,5S)-3-Benzenesulphonyl-8-(3,5-dimethyl-piperazin-1-yl)-2-ethyl-6,7-dihydro-5H-cyclopenta[d]pyrazolo[1,5-a]pyrimidine

[0112] In an analogous manner to that described in Example 12, from 3-benzenesulphonyl-8-chloro-2-ethyl-6,7-dihydro-5H-cyclopenta[d]pyrazolo[1,5-a]pyrimidine and cis-2,6-dimethylpiperazine there was obtained (3R,5S)-3-benzenesulphonyl-8-(3,5-dimethyl-piperazin-1-yl)-2-ethyl-6,7-dihydro-5H-cyclopenta[d]pyrazolo[1,5-a]pyrimidine as colourless crystals, m.p. 220-221°.

Example 793-Benzenesulphonyl-5-methyl-7-piperazin-1-yl-pyrazolo[1,5-a]pyrimidine

5 [0113]

a) 6.88 ml of N,N-dimethylformamide dimethyl acetal were added to a suspension of 7.0 g (38.6 mmol) of phenylsulphonylacetonitrile in 30 ml of hexane while cooling with ice and subsequently stirred at RT for 12 hrs. The separated crystals were filtered off and there were thus obtained 9.08 g (99%) of 2-benzenesulphonyl-3-dimethylamino-acrylonitrile as beige crystals, m.p. 108-110°.

10 b) 2.05 ml (40.9 mmol) of NH_2NH_2 were added to a solution of 9.08 g (38.3 mmol) of 2-benzenesulphonyl-3-dimethylamino-acrylonitrile in 60 ml of EtOH and stirred at 40° for 5 hrs. The reaction solution was evaporated and the residue was partitioned between H_2O and CH_2Cl_2 . The aqueous phase was washed three times with CH_2Cl_2 , and the combined organic phases were dried (MgSO_4), filtered and evaporated. Chromatography (SiO_2 , $\text{CH}_2\text{Cl}_2/\text{MeOH}$ 10:1) yielded 2.5 g (30%) of 4-benzenesulphonyl-1H-pyrazol-3-ylamine as a beige powder, m.p. 159-161°.

15 c) A solution of 1.0 g (4.47 mmol) of 4-benzenesulphonyl-1H-pyrazol-3-ylamine and 0.6 ml (5.37 mmol) of ethyl acetoacetate in 8 ml of acetic acid was heated at reflux for 1.5 hrs. The reaction solution was cooled to RT and evaporated. The residue was partitioned between CH_2Cl_2 and H_2O and the aqueous phase was washed three times with 150 ml of CH_2Cl_2 . The combined organic phases were dried (MgSO_4), filtered and evaporated. Chromatography (SiO_2 , $\text{CH}_2\text{Cl}_2/\text{MeOH}$ 20:1) yielded 0.91 g (70%) of 3-benzenesulphonyl-5-methyl-pyrazolo[1,5-a]pyrimidine as beige crystals.

20 d) A suspension of 0.91 g (3.14 mmol) of 3-benzenesulphonyl-5-methyl-pyrazolo[1,5-a]pyrimidine in 15 ml of POCl_3 was heated at reflux for 1 hr. The reaction solution was cooled to RT and evaporated. The residue was treated with 30 ml of ice-water and the pH value of the solution was adjusted to 8 with sat. NaHCO_3 solution. The aqueous phase was extracted three times with 20 ml of CH_2Cl_2 , and the organic phases were dried (MgSO_4), filtered and evaporated. Chromatography (SiO_2 , $\text{CH}_2\text{Cl}_2/\text{AcOEt}$ 19:1) of the residue yielded 0.84 g (87%) of 3-benzenesulphonyl-7-chloro-5-methyl-pyrazolo[1,5-a]pyrimidine as a beige solid.

25 e) In an analogous manner to that described in Example 1c), from 3-benzenesulphonyl-7-chloro-5-methyl-pyrazolo[1,5-a]pyrimidine and piperazine there was obtained 3-benzenesulphonyl-5-methyl-7-piperazin-1-yl-pyrazolo[1,5-a]pyrimidine as colourless crystals, m.p. 180-181°.

Example 803-Benzenesulphonyl-5-methyl-7-(4-methyl-piperazin-1-yl)-pyrazolo[1,5-a]pyrimidine

35 [0114] In an analogous manner to that described in Example 2, from 3-benzenesulphonyl-7-chloro-5-methyl-pyrazolo[1,5-a]pyrimidine and 1-methyl-piperazine there was obtained 3-benzenesulphonyl-5-methyl-7-(4-methyl-piperazin-1-yl)-pyrazolo[1,5-a]pyrimidine as colourless crystals, m.p. >230.

Example 815-Methyl-2-methylsulphanyl-7-piperazin-1-yl-3-(toluene-2-sulphonyl)-pyrazolo[1,5-a]pyrimidine

45 [0115]

a) In an analogous manner to that described in Example 18 a) to d), starting from (toluene-2-sulphonyl)-acetonitrile there was obtained 7-chloro-5-methyl-2-methylsulphanyl-3-(toluene-2-sulphonyl)-pyrazolo[1,5-a]pyrimidine as a colourless foam.

50 b) In an analogous manner to that described in Example 1c), from 7-chloro-5-methyl-2-methylsulphanyl-3-(toluene-2-sulphonyl)-pyrazolo[1,5-a]pyrimidine and piperazine there was obtained 5-methyl-2-methylsulphanyl-7-piperazin-1-yl-3-(toluene-2-sulphonyl)-pyrazolo[1,5-a]pyrimidine as colourless crystals, m.p. 215-215.5°

[0116] The (toluene-2-sulphonyl)-acetonitrile used was prepared as follows:

55 2.2 ml (34.5 mmol) of chloroacetonitrile were added to a suspension of 4.5 g (28.8 mmol) of toluene-2-sulphinic acid sodium salt in 100 ml of DMF and stirred at 100° for 1 hr. The reaction solution was evaporated and the residue was partitioned between H_2O and CH_2Cl_2 . The aqueous phase was washed three times with CH_2Cl_2 . The combined organic phases were washed once with H_2O , dried (MgSO_4), filtered and evaporated. Chromatography (SiO_2 , CH_2Cl_2) yielded

2.9 g (50%) of (toluene-2-sulphonyl)-acetonitrile as a colourless oil.

Example 82

5 5-Methyl-7-(4-methyl-piperazin-1-yl)-2-methylsulphonyl-3-(toluene-2-sulphonyl)-pyrazolo[1,5-a]pyrimidine

[0117] In an analogous manner to that described in Example 2), from 7-chloro-5-methyl-2-methylsulphonyl-3-(toluene-2-sulphonyl)-pyrazolo[1,5-a]pyrimidine and 1-methyl-piperazine there was obtained 5-methyl-7-(4-methyl-piperazin-1-yl)-2-methylsulphonyl-3-(toluene-2-sulphonyl)-pyrazolo[1,5-a]pyrimidine as colourless crystals, m.p. 199-200°.

Example 83

5-Methyl-2-methylsulphonyl-3-(toluene-2-sulphonyl)-pyrazolo[1,5-a]pyrimidin-7-ylamine

15 [0118] In an analogous manner to that described in Example 4), from 7-chloro-5-methyl-2-methylsulphonyl-3-(toluene-2-sulphonyl)-pyrazolo[1,5-a]pyrimidine and NH_3 in MeOH there was obtained 5-methyl-2-methylsulphonyl-3-(toluene-2-sulphonyl)-pyrazolo[1,5-a]pyrimidin-7-ylamine as colourless crystals, m.p. > 250°.

Example 84

20 5-Methyl-2-methylsulphonyl-7-piperazin-1-yl-3-(toluene-2-sulphonyl)-pyrazolo[1,5-a]pyrimidine

[0119]

25 a) In an analogous manner to that described in Example 18 a) to d), starting from (toluene-3-sulphonyl)-acetonitrile there was obtained 7-chloro-5-methyl-2-methylsulphonyl-3-(toluene-3-sulphonyl)-pyrazolo[1,5-a]pyrimidine as a colourless foam.

b) In an analogous manner to that described in Example 1c), from 7-chloro-5-methyl-2-methylsulphonyl-3-(toluene-2-sulphonyl)-pyrazolo[1,5-a]pyrimidine and piperazine there was obtained 5-methyl-2-methylsulphonyl-7-piperazin-1-yl-3-(toluene-2-sulphonyl)-pyrazolo[1,5-a]pyrimidine as colourless crystals, m.p. 165-165.5°.

The (toluene-3-sulphonyl)-acetonitrile used was prepared as follows:

2.65 ml (42 mmol) of chloroacetonitrile were added to a suspension of 7.5 g (42 mmol) of toluene-3-sulphinic acid sodium salt in 80 ml of DMF and stirred at 100° for 1 hr. The reaction solution was evaporated, the residue was partitioned between H_2O and CH_2Cl_2 . The aqueous phase was washed three times with CH_2Cl_2 . The combined organic phases were washed once with H_2O , dried (MgSO_4), filtered and evaporated. Chromatography (SiO_2 , CH_2Cl_2) yielded 2.06 g (25%) of (toluene-3-sulphonyl)-acetonitrile as a colourless oil.

Example 85

40 5-Methyl-7-(4-methyl-piperazin-1-yl)-2-methylsulphonyl-3-(toluene-3-sulphonyl)-pyrazolo[1,5-a]pyrimidine

[0120] In an analogous manner to that described in Example 2), from 7-chloro-5-methyl-2-methylsulphonyl-3-(toluene-3-sulphonyl)-pyrazolo[1,5-a]pyrimidine and 1-methyl-piperazine there was obtained 5-methyl-7-(4-methyl-piperazin-1-yl)-2-methylsulphonyl-3-(toluene-3-sulphonyl)-pyrazolo[1,5-a]pyrimidine as colourless crystals, m.p. 183-184°.

Example 86

50 5-Methyl-2-methylsulphonyl-3-(toluene-3-sulphonyl)-pyrazolo[1,5-a]pyrimidin-7-ylamine

[0121] In an analogous manner to that described in Example 4), from 7-chloro-5-methyl-2-methylsulphonyl-3-(toluene-3-sulphonyl)-pyrazolo[1,5-a]pyrimidine and NH_3 in MeOH there was obtained 5-methyl-2-methylsulphonyl-3-(toluene-3-sulphonyl)-pyrazolo[1,5-a]pyrimidine-7-ylamine as colourless crystals, m.p. >250°.

Exempl 875-Methyl-2-methylsulphanyl-7-piperazin-1-yl-3-(pyridine-3-sulphonyl)-pyrazolo[1,5-a]pyrimidine**[0122]**

a) In an analogous manner to that described in Example 18 a) to d), starting from (pyridine-3-sulphonyl)-acetonitrile there was obtained 7-chloro-5-methyl-2-methylsulphanyl-3-(pyridine-3-sulphonyl)-pyrazolo[1,5-a]pyrimidine as a colourless foam.

b) In an analogous manner to that described in Example 1c), from 7-chloro-5-methyl-2-methylsulphanyl-3-(pyridine-3-sulphonyl)-pyrazolo[1,5-a]pyrimidine and piperazine there was obtained 5-methyl-2-methylsulphanyl-7-piperazin-1-yl-3-(pyridine-3-sulphonyl)-pyrazolo[1,5-a]pyrimidine as colourless crystals, m.p. 222-223°.

[0123] The (pyridine-3-sulphonyl)-acetonitrile used was prepared as follows:

2.1 ml (33.4 mmol) of chloroacetonitrile were added to a solution of 4.6 g (42 mmol) of pyridine-3-sulphinic acid sodium salt in 50 ml of DMF and stirred at 90° for 1 hr. The reaction solution was evaporated, the residue was partitioned between H₂O and CH₂Cl₂. The aqueous phase was washed three times with CH₂Cl₂. The combined organic phases were washed once with H₂O, dried (MgSO₄) filtered and evaporated. Chromatography (SiO₂, AcOEt/hexane 2:1) yielded 4.1 g (80%) of (pyridine-3-sulphonyl)-acetonitrile as a beige solid.

Example 885-Methyl-7-(4-methyl-piperazin-1-yl)-2-methylsulphanyl-3-(pyridine-3-sulphonyl)-pyrazolo[1,5-a]pyrimidine

[0124] In an analogous manner to that described in Example 2), from 7-chloro-5-methyl-2-methylsulphanyl-3-(pyridine-3-sulphonyl)-pyrazolo[1,5-a]pyrimidine and 1-methyl-piperazine there was obtained 5-methyl-7-(4-methyl-piperazin-1-yl)-2-methylsulphanyl-3-(pyridine-3-sulphonyl)-pyrazolo[1,5-a]pyrimidine as colourless crystals, m.p. 188.4-189°.

Example 895-Methyl-2-methylsulphanyl-3-(pyridine-3-sulphonyl)-pyrazolo[1,5-a]pyrimidin-7-ylamine

[0125] In an analogous manner to that described in Example 4), from 7-chloro-5-methyl-2-methylsulphanyl-3-(pyridine-3-sulphonyl)-pyrazolo[1,5-a]pyrimidine and NH₃ in MeOH there was obtained 5-methyl-2-methylsulphanyl-3-(pyridine-3-sulphonyl)-pyrazolo[1,5-a]pyrimidin-7-ylamine as colourless crystals, m.p. 226.8 -227.5°.

Example 902-[3-Benzenesulphonyl-5-methyl-7-(4-methyl-piperazin-1-yl)-2-methylsulphanyl-pyrazolo[1,5-a]pyrimidin-6-yl]-ethanol**[0126]**

a) A solution of 2.69 g (10 mmol) of 4-benzenesulphonyl-5-methylsulphanyl-2H-pyrazol-3-ylamine and 1.28 g (10 mmol) of 2-acetyl-butylolactone in 10 ml of acetic acid was heated at reflux for 1.5 hrs. After cooling to RT the mixture was treated with 50 ml of H₂O and extracted three times with CH₂Cl₂. The organic phases were dried (MgSO₄), filtered and evaporated. Chromatography (SiO₂, CH₂Cl₂/MeOH 20:1) of the residue yielded 1.5 g (36%) of ethyl 2-(3-benzenesulphonyl-7-hydroxy-5-methyl-2-methylsulphanyl-pyrazolo[1,5-a]pyrimidin-6-yl)-acetate as a colourless foam.

b) A suspension of 1.5 g (3.56 mmol) of ethyl 2-(3-benzenesulphonyl-7-hydroxy-5-methyl-2-methylsulphanyl-pyrazolo[1,5-a]pyrimidin-6-yl)-acetate in 30 ml of POCl₃ was heated at reflux for 4 hrs. The reaction solution was cooled to RT and evaporated. The residue was treated with 100 ml of ice-water and the pH value of the solution was adjusted to 8 with sat. NaHCO₃ solution. The aqueous phase was extracted three times with 70 ml of CH₂Cl₂, and the organic phases were dried (MgSO₄), filtered and evaporated. Chromatography (SiO₂, CH₂Cl₂ 20:1) of the residue yielded 1.0 g (94%) of ethyl 2-(3-benzenesulphonyl-7-chloro-5-methyl-2-methylsulphanyl-pyrazolo[1,5-a]pyrimidin-6-yl)-acetate as a pale yellow solid.

c) 0.1 g (1 mmol) of 1-methyl-piperazine in 5 ml of DMF was added to a solution of 0.35 g (0.8 mmol) of ethyl 2-(3-benzenesulphonyl-7-chloro-5-methyl-2-methylsulphonyl-pyrazolo[1,5-a]pyrimidin-6-yl)-acetate in 15 ml of DMF and stirred at 60° for 2 hrs. The DMF was evaporated in a high vacuum, the residue was partitioned between 2N NaOH and CH₂Cl₂, the aqueous phase was extracted three times with CH₂Cl₂. The combined organic phases were dried (MgSO₄), filtered and evaporated. Subsequent chromatography (SiO₂, CH₂Cl₂/MeOH 10:1) yielded 0.34 g of a yellow foam, which was dissolved in a mixture of 50 ml of tetrahydrofuran/dioxan/H₂O 1:1:1. After the addition of 4 ml of 2N NaOH the mixture was stirred at 45° for 12 hrs., treated with 100 ml of H₂O and extracted three times with 60 ml of CH₂Cl₂. The combined organic phases were dried (MgSO₄), filtered and evaporated. Chromatography (SiO₂, CH₂Cl₂/MeOH 8:1) yielded 0.18 mg (48%) of 2-[3-benzenesulphonyl-5-methyl-7-(4-methyl-piperazin-1-yl)-2-methylsulphonyl-pyrazolo[1,5-a]pyrimidin-6-yl]-ethanol as a colourless foam.

Example 91

2-[3-Benzenesulphonyl-5-methyl-7-(4-methyl-piperazin-1-yl)-pyrazolo[1,5-a]pyrimidin-2-yloxy]-ethanol

[0127]

a) 0.88 g (22 mmol) of powdered NaOH was added to a solution of 2 g (11 mmol) of phenylsulphonylacetone in 20 ml of acetonitrile and stirred at RT for 2 hrs. Subsequently, a solution of 1.14 ml (11 mmol) of 2-chloroethyl chloroformate in 4 ml of acetonitrile was added dropwise thereto at 5° and the mixture was heated at reflux for 1 hr. After cooling to RT the precipitate was filtered off and the filtrate was evaporated. The thus-obtained brown oil was taken up in 50 ml of EtOH and treated with 0.54 ml (11 mmol) of NH₂NH₂ and heated at reflux for 1 hr. After evaporation of the reaction solution and subsequent chromatography (SiO₂, CH₂Cl₂/MeOH/NH₄OH 110:10:1) there were obtained 1.4 g (45%) of 2-(5-amino-4-benzenesulphonyl-1H-pyrazol-3-yloxy)-ethanol as a colourless solid.

b) 0.75 ml of ethyl acetoacetate was added to a solution of 1.14 g (4.9 mmol) of 2-(5-amino-4-benzenesulphonyl-1H-pyrazol-3-yloxy)-ethanol in 10 ml of acetic acid and heated at reflux for 3 hrs. After cooling to RT the mixture was treated with 50 ml of H₂O and extracted three times with CH₂Cl₂. The organic phases were dried (MgSO₄), filtered and evaporated. Chromatography (SiO₂, CH₂Cl₂/MeOH 19:1) of the residue yielded 0.8 g (42%) of ethyl 2-(3-benzenesulphonyl-7-hydroxy-5-methyl-pyrazolo[1,5-a]pyrimidin-2-yloxy)-acetate as a colourless oil.

c) A suspension of 0.8 g (2 mmol) of ethyl 2-(3-benzenesulphonyl-7-hydroxy-5-methylpyrazolo[1,5-a]pyrimidin-2-yloxy)-acetate in 20 ml of POCl₃ was heated at reflux for 4 hrs. The reaction solution was cooled to RT and evaporated. The residue was treated with 80 ml of ice-water and the pH value of the solution was adjusted to 8 with sat. NaHCO₃ solution. The aqueous phase was extracted three times with 70 ml of CH₂Cl₂, and the organic phases were dried (MgSO₄), filtered and evaporated. Chromatography (SiO₂, CH₂Cl₂/MeOH 40:1) of the residue yielded 0.56 g (68%) of ethyl 2-[3-benzenesulphonyl-5-methyl-7-(4-methyl-piperazin-1-yl)-pyrazolo[1,5-a]pyrimidin-2-yloxy]-acetate as a colourless solid.

d) 0.38 ml (3.4 mmol) of 1-methyl-piperazine in 5 ml of DMF was added to a solution of 0.56 g (1.4 mmol) of ethyl 2-[3-benzenesulphonyl-5-methyl-7-(4-methyl-piperazin-1-yl)-pyrazolo[1,5-a]pyrimidin-2-yloxy]-acetate in 10 ml of DMF and stirred at RT for 1.5 hrs. The DMF was evaporated in a high vacuum, and the residue was partitioned between 2N NaOH and CH₂Cl₂. The aqueous phase was extracted three times with CH₂Cl₂, and the combined organic phases were dried (MgSO₄), filtered and evaporated. Subsequent chromatography (silica gel, CH₂Cl₂/MeOH 19:1) yielded 0.61 g (92%) of ethyl 2-[3-benzenesulphonyl-5-methyl-7-(4-methyl-piperazin-1-yl)-pyrazolo[1,5-a]pyrimidin-2-yloxy]-acetate as a colourless foam.

e) A solution of 0.126 g of KOH in 5 ml of H₂O was added to a solution of 0.61 mg of ethyl 2-[3-benzenesulphonyl-5-methyl-7-(4-methyl-piperazin-1-yl)-pyrazolo[1,5-a]pyrimidin-2-yloxy]-acetate in 20 ml of dioxan/THF 1:1 and stirred at RT for 2.5 hrs. The reaction solution was evaporated and the residue was partitioned between H₂O and CH₂Cl₂. The aqueous phase was washed three times with 30 ml of CH₂Cl₂, and the combined organic phases were dried (MgSO₄), filtered and evaporated. Chromatography (SiO₂, CH₂Cl₂/MeOH 9:1) of the residue and crystallization from EtOH yielded 0.18 g (18%) of 2-[3-benzenesulphonyl-5-methyl-7-(4-methyl-piperazin-1-yl)-pyrazolo[1,5-a]pyrimidin-2-yloxy]-ethanol as colourless crystals. M.p. 177.5-178°.

Example 923-Benzenesulphonyl-5-(2-methoxy-ethyl)-2-methylsulphonyl-7-piperazin-1-yl-pyrazolo[1,5-a]pyrimidine

[0128]

a) A solution of 2.69 g (10 mmol) of 4-benzenesulphonyl-5-methylsulphonyl-2H-pyrazol-3-ylamine and 1.6 g (10 mmol) of methyl 5-methoxy-3-oxo-valerate in 10 ml of acetic acid was heated at reflux for 4 hrs. The reaction solution was evaporated and the residue was partitioned between H₂O and CH₂Cl₂. The aqueous phase was extracted three times with 80 ml of CH₂Cl₂. The combined organic phases were dried (MgSO₄), filtered and evaporated. Chromatography (SiO₂, CH₂Cl₂/MeOH 20:1) yielded 2.40 g (61%) of 3-benzenesulphonyl-5-(2-methoxy-ethyl)-2-methylsulphonyl-pyrazolo[1,5-a]pyrimidin-7-ol as a beige powder.

b) A suspension of 2.3 g (6.0 mmol) of 3-benzenesulphonyl-5-(2-methoxy-ethyl)-2-methylsulphonyl-pyrazolo[1,5-a]pyrimidin-7-ol in 40 ml of POCl₃ and 20 ml of diethylaniline was heated at reflux for 1 hr. The reaction solution was cooled to RT and evaporated. The residue was treated with 100 ml of ice-water and the pH value of the solution was adjusted to 8 with sat. NaHCO₃ solution. The aqueous phase was extracted three times with 100 ml of CH₂Cl₂, and the organic phases were dried (MgSO₄), filtered and evaporated. Chromatography (SiO₂, CH₂Cl₂/MeOH 200:1) of the residue yielded 1.8 g (75%) of 3-benzenesulphonyl-7-chloro-5-(2-methoxy-ethyl)-2-methylsulphonyl-pyrazolo[1,5-a]pyrimidine as a pale yellow powder.

c) 0.4 g (4.8 mmol) of piperazine in 3 ml of DMF was added to a solution of 0.35 g (0.8 mmol) of 3-benzenesulphonyl-7-chloro-5-(2-methoxy-ethyl)-2-methylsulphonylpyrazolo[1,5-a]pyrimidine in 10 ml of DMF and stirred at RT for 2 hrs. The reaction solution was evaporated, the residue was partitioned between 2N NaOH and CH₂Cl₂. The aqueous phase was extracted three times with CH₂Cl₂, the combined organic phases were dried (MgSO₄), filtered and evaporated. Subsequent chromatography (SiO₂, CH₂Cl₂/MeOH 8:1) and crystallization from EtOH yielded 0.25 g (62%) of 3-benzenesulphonyl-5-(2-methoxy-ethyl)-2-methylsulphonyl-7-piperazin-1-yl-pyrazolo[1,5-a]pyrimidine as colourless crystals, m.p. 155-156°.

Example 933-Benzenesulphonyl-5-(2-methoxy-ethyl)-7-(4-methyl-piperazin-1-yl)-2-methylsulphonyl-pyrazolo[1,5-a]pyrimidine

[0129] 0.5 g (5 mmol) of 1-methyl-piperazine in 3 ml of DMF was added to a solution of 0.45 g (1.13 mmol) of 3-benzenesulphonyl-7-chloro-5-(2-methoxy-ethyl)-2-methylsulphonylpyrazolo[1,5-a]pyrimidine in 20 ml of DMF and stirred at RT for 3 hrs. The reaction solution was evaporated, the residue was partitioned between 2N NaOH and CH₂Cl₂. The aqueous phase was extracted three times with CH₂Cl₂, the combined organic phases were dried (MgSO₄), filtered and evaporated. Subsequent chromatography (silica gel, CH₂Cl₂/MeOH 12:1) and crystallization from EtOH yielded 0.255 g (67%) of 3-benzenesulphonyl-5-(2-methoxy-ethyl)-7-(4-methyl-piperazin-1-yl)-2-methylsulphonyl-pyrazolo[1,5-a]pyrimidine as colourless crystals, m.p. 160-161°.

Example 943-Benzenesulphonyl-5-(2-methoxy-ethyl)-2-methylsulphonyl-pyrazolo[1,5-a]pyrimidin-7-ylamine

[0130] 10 ml of a 50% solution of NH₃ in MeOH were added to a solution of 0.50 g (1.25 mmol) of 3-benzenesulphonyl-7-chloro-5-(2-methoxy-ethyl)-2-methylsulphonyl-pyrazolo[1,5-a]pyrimidine in 10 ml of DMF and stirred at RT for 2 hrs. The reaction solution was evaporated in a high vacuum and the residue was partitioned between 2N NaOH and CH₂Cl₂. The aqueous phase was extracted three times with CH₂Cl₂ and the combined organic phases were dried (MgSO₄), filtered and evaporated. Subsequent chromatography (SiO₂, CH₂Cl₂/MeOH 10:1) and crystallization from EtOH yielded 0.30 g (63%) of 3-benzenesulphonyl-5-(2-methoxy-ethyl)-2-methylsulphonyl-pyrazolo[1,5-a]pyrimidin-7-ylamine as colourless crystals, m.p. 186-187°.

Example 953-Benzenesulphonyl-5-(2-methoxy-ethyl)-2-methylsulphonyl-7-piperazin-1-yl-pyrazolo[1,5-a]pyrimidine

[0131]

a) A solution of 2.69 g (10 mmol) 4-benzenesulphonyl-5-methylsulphonyl-2H-pyrazol-3-ylamine and 1.46 g (10

mmol) of ethyl 4-methoxy-acetoacetate in 10 ml of acetic acid was heated at reflux for 3 hrs. The reaction solution was evaporated and the residue was partitioned between H₂O and CH₂Cl₂. The aqueous phase was extracted three times with 80 ml of CH₂Cl₂. The combined organic phases were dried (MgSO₄), filtered and evaporated. Chromatography (SiO₂, CH₂Cl₂/MeOH 25:1) yielded 3.1 g (85%) of 3-benz nesulphonyl-5-methoxymethyl-2-methylsulphanyl-pyrazolo[1,5-a]pyrimidin-7-ol as a beige powder, m.p. 175-155°.

b) A suspension of 2.5 g (6.8 mmol) of 3-benzenesulphonyl-5-methoxymethyl-2-methylsulphanyl-pyrazolo[1,5-a]pyrimidin-7-ol in 40 ml of POCl₃ and 20 ml of diethylaniline was heated at reflux for 1 hr. The reaction solution was cooled to RT and evaporated. The residue was treated with 100 ml of ice-water and the pH value of the solution was adjusted to 8 with sat. NaHCO₃ solution. The aqueous phase was extracted three times with 100 ml of CH₂Cl₂, and the organic phases were dried (MgSO₄), filtered and evaporated. Chromatography (SiO₂, CH₂Cl₂/MeOH 20:1) yielded 2.1 g (79%) of 3-benzenesulphonyl-7-chloro-5-methoxymethyl-2-methylsulphanyl-pyrazolo[1,5-a]pyrimidine as a pale yellow powder, m.p. 194-197°.

c) 0.4 g (4.8 mmol) of piperazine in 3 ml of DMF was added to a solution of 0.50 g (1.13 mmol) of 3-benzenesulphonyl-7-chloro-5-methoxymethyl-2-methylsulphanyl-pyrazolo[1,5-a]pyrimidine in 15 ml of DMF and stirred at RT for 2 hrs. The reaction solution was evaporated and the residue was partitioned between 2N NaOH and CH₂Cl₂. The aqueous phase was extracted three times with CH₂Cl₂, and the combined organic phases were dried (MgSO₄), filtered and evaporated. Subsequent chromatography (SiO₂, CH₂Cl₂/ MeOH 8:1) and crystallization from EtOH yielded 0.42 g (74%) of 3-benzenesulphonyl-5-(2-methoxy-ethyl)-2-methylsulphanyl-7-piperazin-1-yl-pyrazolo [1,5-a]pyrimidine as colourless crystals, m.p. 170-171°.

Example 96

3-Benzenesulphonyl-5-methoxymethyl-7-(4-methyl-piperazin-1-yl)-2-methylsulphanyl-pyrazolo[1,5-a]pyrimidine

[0132] 0.50 g (5 mmol) of 1-methyl-piperazine in 3 ml of DMF was added to a solution of 0.50 g (1.3 mmol) of 3-benzenesulphonyl-7-chloro-5-methoxymethyl-2-methylsulphanyl-pyrazolo[1,5-a]pyrimidine in 15 ml of DMF and stirred at RT for 2 hrs. The reaction solution was evaporated and the residue was partitioned between 2N NaOH and CH₂Cl₂. The aqueous phase was extracted three times with CH₂Cl₂, and the combined organic phases were dried (MgSO₄), filtered and evaporated. Subsequent chromatography (SiO₂, CH₂Cl₂/ MeOH 10:1) and crystallization from EtOH yielded 0.42 g (72%) of 3-benzenesulphonyl-5-methoxy- methyl-7-(4-methyl-piperazin-1-yl)-2-methylsulphanyl-pyrazolo[1,5-a]pyrimidine as colorless crystals, m.p. 207-208°.

Example 97

3-Benzenesulphonyl-5-methoxymethyl-2-methylsulphanyl-pyrazolo[1,5-a]pyrimidin-7-ylamine

[0133] 10 ml of a 50% solution of NH₃ in MeOH was added to a solution of 0.50 g (1.3 mmol) of 3-benzenesulphonyl-7-chloro-5-methoxymethyl-2-methylsulphanyl-pyrazolo[1,5-a]pyrimidine in 10 ml of DMF and stirred at RT for 2 hrs. The reaction solution was evaporated and the residue was partitioned between 2N NaOH and CH₂Cl₂. The aqueous phase was extracted three times with CH₂Cl₂, and the combined organic phases were dried (MgSO₄), filtered and evaporated. Subsequent chromatography (SiO₂, CH₂Cl₂/MeOH 10:1) and crystallization from EtOH yielded 0.38 g (80%) of 3-benzenesulphonyl-5-methoxymethyl-2-methylsulphanyl-pyrazolo[1,5-a]pyrimidin-7-ylamine as colourless crystals, m.p. >230°.

Example 98

3-Benzenesulphonyl-5-chloro-7-(4-methyl-piperazin-1-yl)-2-methylsulphanyl-pyrazolo [1,5-a]pyrimidine

[0134]

a) 5.38 g (20 mmol) of 4-benzenesulphonyl-5-methylsulphanyl-2H-pyrazol-3-ylamine followed by 9 ml (60 mmol) of diethyl malonate were added to a freshly prepared solution of sodium ethanolate in EtOH (prepared from 0.89 g (77 mmol) of sodium in 100 ml of EtOH) and the mixture was heated at reflux for 48 hrs. After cooling to RT the mixture was subsequently poured on to 140 ml of ice-water. The resulting precipitate was filtered off and dried at 50° in a high vacuum. There were thus obtained 6.5 g (96%) of 3-benzenesulphonyl-2-methylsulphanyl-pyrazolo [1,5-a]pyrimidine-5,7-diol as a beige powder, m.p. >230°.

b) A suspension of 3.0 g (8.89 mmol) of 3-benzenesulphonyl-2-methylsulphanyl-pyrazolo[1,5-a]pyrimidine-5,7-diol in 40 ml of POCl₃ was heated at reflux for 1 hr. The reaction solution was cooled to RT and evaporated. The residue

was treated with 100 ml of ice-water and the pH value of the solution was adjusted to 8 with sat. NaHCO_3 solution. The aqueous phase was extracted three times with 90 ml of CH_2Cl_2 , and the organic phases were dried (MgSO_4), filtered and evaporated. Chromatography (SiO_2 , $\text{CH}_2\text{Cl}_2/\text{AcOEt}$ 1.5:1) of the residue yielded 1.8 g (54%) of 3-benzenesulphonyl-5,7-dichloro-2-methylsulphonyl-pyrazolo[1,5-a]pyrimidine as colourless crystals, m.p. 193-197°.

c) 0.1 g (1 mmol) of 1-methyl-piperazine in 3 ml of CH_2Cl_2 was added to a solution of 0.37 g (1 mmol) of 3-benzenesulphonyl-5,7-dichloro-2-methylsulphonyl-pyrazolo[1,5-a]pyrimidine in 20 ml of CH_2Cl_2 and stirred at RT for 1 hr. The mixture was poured on to ice-water, adjusted to pH 8 with NaHCO_3 solution and extracted three times with 30 ml of CH_2Cl_2 . The combined organic phases were dried (MgSO_4), filtered and evaporated. Subsequent chromatography (silica gel, $\text{CH}_2\text{Cl}_2/\text{MeOH}$ 4:1) yielded 0.38 g (86%) of 3-benzenesulphonyl-5-chloro-7-(4-methyl-piperazin-1-yl)-2-methylsulphonyl-pyrazolo[1,5-a]pyrimidine as colourless crystals, m.p. >230°.

Example 993-Benzenesulphonyl-7-(4-methyl-piperazin-1-yl)-2-methylsulphonyl-pyrazolo[1,5-a]pyrimidine

[0135] 0.15 g of Pd/C (10%) and 0.3 ml of NEt_3 were added to a solution of 0.189 g (0.4 mmol) of 3-benzenesulphonyl-5-chloro-7-(4-methyl-piperazin-1-yl)-2-methylsulphonyl-pyrazolo[1,5-a]pyrimidine in 30 ml of EtOH and hydrogenated at RT for 12 hrs. The reaction mixture was filtered over Dicalite and the filtrate was evaporated. Chromatography of the residue (SiO_2 , $\text{CH}_2\text{Cl}_2/\text{MeOH}$ 20:1) yielded 0.08 g (49%) of 3-benzenesulphonyl-7-(4-methyl-piperazin-1-yl)-2-methylsulphonyl-pyrazolo[1,5-a]pyrimidine as colourless crystals, m.p. 107-109°.

Example 1002-[3-Benzenesulphonyl-7-(4-methyl-piperazin-1-yl)-2-methylsulphonyl-pyrazolo[1,5-a]pyrimidin-5-yloxy]-ethanol

[0136] 0.115 g (5 mmol) of sodium was added to 20 ml of ethylene glycol and this solution was treated with 0.22 g (0.5 mmol) of 3-benzenesulphonyl-5-chloro-7-(4-methyl-piperazin-1-yl)-2-methylsulphonyl-pyrazolo[1,5-a]pyrimidine and subsequently stirred at 80° for 1 hr. After cooling to RT the reaction solution was poured on to 70 ml of ice-water and extracted three times with 50 ml of AcOEt. The combined organic phases were dried (MgSO_4), filtered and evaporated. Chromatography (SiO_2 , $\text{CH}_2\text{Cl}_2/\text{MeOH}/\text{NH}_4\text{OH}$ 110:10:1) of the residue and crystallization from EtOH yielded 0.16 g (69%) of 2-[3-benzenesulphonyl-7-(4-methyl-piperazin-1-yl)-2-methylsulphonyl-pyrazolo[1,5-a]pyrimidin-5-yloxy]-ethanol as colourless crystals, m.p. 187-189°.

Example 1013-Benzenesulphonyl-5-chloro-2-methylsulphonyl-pyrazolo[1,5-a]pyrimidin-7-ylamine

[0137] 10 ml of a 50% solution of NH_3 in MeOH were added to a solution of 0.35 g (0.935 mmol) of 3-benzenesulphonyl-5,7-dichloro-2-methylsulphonyl-pyrazolo[1,5-a]pyrimidine in 10 ml of DMF and stirred at RT for 12 hrs. The DMF was evaporated in a high vacuum and the residue was partitioned between 2N NaOH and CH_2Cl_2 . The aqueous phase was extracted three times with CH_2Cl_2 , and the combined organic phases were dried (MgSO_4), filtered and evaporated. Subsequent chromatography (silica gel, $\text{CH}_2\text{Cl}_2/\text{AcOEt}$ 15:1) and crystallization from EtOH yielded 0.28 g (84%) of 3-benzenesulphonyl-5-chloro-2-methylsulphonyl-pyrazolo[1,5-a]pyrimidin-7-ylamine as colourless crystals, m.p. >230°.

Example 1023-Benzenesulphonyl-N5,N5-dimethyl-2-methylsulphonyl-pyrazolo[1,5-a]pyrimidine-5,7-diamine and3-benzenesulphonyl-N5-(2-dimethylamino-ethyl)-2-methylsulphonyl-pyrazolo[1,5-a]pyrimidine-5,7-diamine

[0138] 0.26 g (3 mmol) of 2-dimethylaminoethylamine in 5 ml of DMF was added to a solution of 0.4 g (1 mmol) of 3-benzenesulphonyl-5-chloro-2-methylsulphonyl-pyrazolo[1,5-a]pyrimidin-7-ylamine in 10 ml of DMF and stirred at 90° for 1 hr. The reaction solution was evaporated and the residue was partitioned between H_2O and CH_2Cl_2 . The aqueous phase was extracted three times with 50 ml of CH_2Cl_2 . The combined organic phases were dried (MgSO_4), filtered and evaporated. Subsequent chromatography (silica gel, $\text{CH}_2\text{Cl}_2/\text{MeOH}$ 8:1) yielded 0.20 g (48%) of 3-benzenesulphonyl-N5,N5-dimethyl-2-methylsulphonyl-pyrazolo[1,5-a]pyrimidine-5,7-diamine as colourless crystals, m.p. >230°, and 0.08 g (17%) of 3-benzenesulphonyl-N5-(2-dimethylamino-ethyl)-2-methylsulphonyl-pyrazolo[1,5-a]pyrimidine-5,7-di-

amine as colourless crystals, m.p. 210-212°.

Example 103

3-Benzenesulphonyl-5-(4-methyl-piperazin-1-yl)-2-methylsulphonyl-pyrazolo[1,5-a] pyrimidin-7-ylamine

[0139] 0.1 g (1 mmol) of 1-methyl-piperazine was added to a solution of 0.14 g (0.4 mmol) of 3-benzenesulphonyl-5-chloro-2-methylsulphonyl-pyrazolo[1,5-a]pyrimidin-7-ylamine in 5 ml of DMF and stirred at 90° for 1 hr. The reaction solution was evaporated and the residue was partitioned between H₂O and CH₂Cl₂. The aqueous phase was extracted three times with 50 ml of CH₂Cl₂. The combined organic phases were dried (MgSO₄), filtered and evaporated. Subsequent chromatography (silica gel CH₂Cl₂/MeOH 9:1) and crystallization from EtOH yielded 0.1 g (59%) of 3-benzenesulphonyl-5-(4-methyl-piperazin-1-yl)-2-methylsulphonyl-pyrazolo[1,5-a]pyrimidin-7-ylamine as colourless crystals, m.p. >230°.

Example 104

3-Benzenesulphonyl-5-chloro-2-ethyl-7-(4-methyl-piperazin-1-yl)-pyrazolo[1,5-a]pyrimidine

[0140]

a) 7.90 g (31.4 mmol) of 4-benzenesulphonyl-5-ethyl-2H-pyrazol-3-ylamine followed by 14.3 ml (94.3 mmol) of diethyl malonate were added to a freshly prepared solution of sodium ethanolate in EtOH (prepared from 2.7 g (119.5 mmol) of sodium in 320 ml of EtOH) and heated at reflux for 48 hrs. After cooling to RT the mixture was subsequently poured into 140 ml of ice-water. The resulting precipitate was filtered off and dried at 50° in a high vacuum. There were thus obtained 4.8 g (48%) of 3-benzenesulphonyl-2-ethyl-pyrazolo-[1,5-a]pyrimidine-5,7-diol, m.p. >230°.

b) A suspension of 2.8 g (8.8 mmol) of 3-benzenesulphonyl-2-ethyl-pyrazolo[1,5-a]pyrimidine-5,7-diol in 30 ml of POCl₃ was heated at reflux for 1 hr. The reaction solution was cooled to RT and evaporated. The residue was treated with 100 ml of ice-water and the pH value of the solution was adjusted to 8 with sat. NaHCO₃ solution. The aqueous phase was extracted three times with 100 ml of CH₂Cl₂, and the organic phases were dried (MgSO₄), filtered and evaporated. Chromatography (SiO₂, CH₂Cl₂) of the residue yielded 1.1 g (35%) of 3-benzenesulphonyl-5,7-dichloro-2-ethyl-pyrazolo[1,5-a]pyrimidine as a colourless solid.

c) 0.86 ml (7.7 mmol) of 1-methyl-piperazine in 3 ml of CH₂Cl₂ was added to a solution of 2.5 g (7 mmol) of 3-benzenesulphonyl-5,7-dichloro-2-ethyl-pyrazolo[1,5-a]pyrimidine in 20 ml of CH₂Cl₂ and stirred at RT for 2 hrs. The reaction mixture was poured on to ice-water, adjusted to pH 8 with NaHCO₃ solution and extracted three times with CH₂Cl₂.

The combined organic phases were dried (MgSO₄), filtered and evaporated. Subsequent chromatography (silica gel, CH₂Cl₂/MeOH 4:1) and crystallization from EtOH yielded 2.5 g (85%) of 3-benzenesulphonyl-5,7-dichloro-2-ethyl-pyrazolo[1,5-a]pyrimidine as colourless crystals, m.p. 166-167°.

Example 105

3-Benzenesulphonyl-2-ethyl-7-(4-methyl-piperazin-1-yl)-pyrazolo[1,5-a]pyrimidine

[0141] 0.1 g of Pd/C (10%) was added to a solution of 0.267 g (0.63 mmol) of 3-benzenesulphonyl-5-chloro-2-ethyl-7-(4-methyl-piperazin-1-yl)-pyrazolo[1,5-a]pyrimidine in 40 ml of EtOH and the mixture was hydrogenated at RT for 4 hrs. The reaction mixture was filtered over Dicalite and the filtrate was evaporated. The residue was partitioned between CH₂Cl₂ and sat. NaHCO₃ solution. The aqueous phase was extracted three times with CH₂Cl₂. The combined organic phases were dried (MgSO₄), filtered and evaporated. Chromatography of the residue (SiO₂CH₂Cl₂/MeOH 19:1) and crystallization from EtOH yielded 0.2 g (53%) of as pale beige crystals, m.p. 206-207°.

Example 106

3-Benzenesulphonyl-2-ethyl-5,7-bis-(4-methyl-piperazin-1-yl)-pyrazolo[1,5-a]pyrimidine

[0142] 0.33 ml (3 mmol) of 1-methyl-piperazine in 5 ml of DMF was added to a solution of 0.50 g (1.2 mmol) of 3-benzenesulphonyl-5-chloro-2-ethyl-7-(4-methyl-piperazin-1-yl)-pyrazolo[1,5-a]pyrimidine in 15 ml of DMF and stirred at 100° for 1 hr. After cooling to RT the reaction solution was evaporated and the residue was partitioned between 2N

NaOH and CH_2Cl_2 . The aqueous phase was extracted three times with CH_2Cl_2 , and the combined organic phases were dried (MgSO_4), filtered and evaporated. Subsequent chromatography (SiO_2 , $\text{CH}_2\text{Cl}_2/\text{MeOH}/\text{NH}_4\text{OH}$ 110:10:1) and crystallization from EtOH yielded 0.04 g (69%) of 3-benzenesulphonyl-2-ethyl-5,7-bis-(4-methyl-piperazin-1-yl)-pyrazolo[1,5-a]pyrimidine as colourless crystals, m.p. 232-235°.

Example 107

3-Benzenesulphonyl-2-ethyl-7-(4-methyl-piperazin-1-yl)-5-morpholin-4-yl-pyrazolo[1,5-a]-pyrimidine

[0143] 0.26 ml (3 mmol) of morpholine in 5 ml of DMF was added to a solution of 0.50 g (1.2 mmol) of 3-benzenesulphonyl-5-chloro-2-ethyl-7-(4-methyl-piperazin-1-yl)-pyrazolo[1,5-a]pyrimidine in 15 ml of DMF and stirred at 100° for 1 hr. After cooling to RT the reaction solution was evaporated and the residue was partitioned between 2N NaOH and CH_2Cl_2 . The aqueous phase was extracted three times with CH_2Cl_2 , and the combined organic phases were dried (MgSO_4), filtered and evaporated. Subsequent chromatography (SiO_2 , $\text{CH}_2\text{Cl}_2/\text{MeOH}$ 15:1) and crystallization from EtOH yielded 0.45 g (80%) of 3-benzenesulphonyl-2-ethyl-7-(4-methyl-piperazin-1-yl)-5-morpholin-4-yl-pyrazolo[1,5-a]pyrimidine as colourless crystals, m.p. >250°.

Example 108

2-[3-Benzenesulphonyl-2-ethyl-7-(4-methyl-piperazin-1-yl)-pyrazolo[1,5-a]pyrimidin-5-yl-oxy]-ethanol

[0144] 0.274 g (12 mmol) of sodium was added to 40 ml of ethylene glycol and this solution was treated with 0.50 g (1.2 mmol) of 3-benzenesulphonyl-5-chloro-2-ethyl-7-(4-methyl-piperazin-1-yl)-pyrazolo[1,5-a]pyrimidine and subsequently stirred at 80° for 1 hr. After cooling to RT the reaction solution was poured on to 70 ml of ice-water and extracted three times with 50 ml of AcOEt. The combined organic phases were dried (MgSO_4), filtered and evaporated. Chromatography (SiO_2 , $\text{CH}_2\text{Cl}_2/\text{MeOH}$ 9:1) of the residue and crystallization from EtOH yielded 0.24 g (44%) of 2-[3-benzenesulphonyl-2-ethyl-7-(4-methyl-piperazin-1-yl)-pyrazolo[1,5-a]pyrimidin-5-yl-oxy]-ethanol as colourless crystals, m.p. 153-154°.

Example 109

[3-Benzenesulphonyl-2-ethyl-7-(4-methyl-piperazin-1-yl)-pyrazolo[1,5-a]pyrimidin-5-yl]-dimethyl-amine and

N-[3-benzenesulphonyl-2-ethyl-7-(4-methyl-piperazin-1-yl)-pyrazolo[1,5-a]pyrimidin-5-yl]-N',N'-dimethyl-ethane-1,2-diamine

[0145] 0.72 g (6.5 mmol) of 2-dimethylaminoethylamine in 5 ml of DMF was added to a solution of 1.1 g (2.6 mmol) of 3-benzenesulphonyl-5-chloro-2-ethyl-7-(4-methyl-piperazin-1-yl)-pyrazolo[1,5-a]pyrimidine in 20 ml of DMF and stirred at 90° for 1 hr. After cooling to RT the reaction solution was evaporated and the residue was partitioned between 2N NaOH and CH_2Cl_2 . The aqueous phase was extracted three times with 80 ml of CH_2Cl_2 . The combined organic phases were dried (MgSO_4), filtered and evaporated. Subsequent chromatography (silica gel, $\text{CH}_2\text{Cl}_2/\text{MeOH}/\text{NH}_4\text{OH}$ 65:10:1) yielded 0.20 g (13%) of [3-benzenesulphonyl-2-ethyl-7-(4-methyl-piperazin-1-yl)-pyrazolo[1,5-a]pyrimidin-5-yl]-dimethyl-amine as colourless crystals, m.p. 211-212°, and 0.30 g (24%) of N-[3-benzenesulphonyl-2-ethyl-7-(4-methyl-piperazin-1-yl)-pyrazolo[1,5-a]pyrimidin-5-yl]-N',N'-dimethyl-ethane-1,2-diamine as colourless crystals, m.p. 163-164°.

Example 110

3-Benzenesulphonyl-5-chloro-2-ethyl-pyrazolo[1,5-a]pyrimidin-7-ylamine

[0146] 20 ml of a 50% solution of NH_3 in MeOH were added to a solution of 1.1 g (3.1 mmol) of 3-benzenesulphonyl-2-ethyl-pyrazolo[1,5-a]pyrimidine-5,7-diol in 10 ml of DMF and stirred at RT for 12 hrs. The reaction solution was evaporated and the residue was partitioned between 2N NaOH and CH_2Cl_2 . The aqueous phase was extracted three times with CH_2Cl_2 and the combined organic phases were dried (MgSO_4), filtered and evaporated. The residue was treated with 5 ml of EtOH and the crystals obtained were filtered off. There was thus obtained 0.80 g (77%) of 3-benzenesulphonyl-5-chloro-2-ethyl-pyrazolo[1,5-a]pyrimidin-7-ylamine as colourless crystals, m.p. >220°.

Exempl 1113-Benzenesulphonyl-2-ethyl-5-(4-methyl-piperazin-1-yl)-pyrazolo[1,5-a]pyrimidin-7-yl-amine

5 [0147] 0.33 ml (3 mmol) of 1-methyl-piperazine was added to a solution of 0.4 g (1.2 mmol) of 3-benzenesulphonyl-5-chloro-2-ethyl-pyrazolo[1,5-a]pyrimidin-7-ylamine in 5 ml of DMF and stirred at 90° for 1 hr. The reaction solution was evaporated and the residue was partitioned between H₂O and CH₂Cl₂. The aqueous phase was extracted three times with 50 ml of CH₂Cl₂. The combined organic phases were dried (MgSO₄), filtered and evaporated. Subsequent chromatography (silica gel, CH₂Cl₂/MeOH 9:1) and crystallization from EtOH yielded 0.24 g (50%) of 3-benzenesulphonyl-2-ethyl-5-(4-methyl-piperazin-1-yl)-pyrazolo[1,5-a]pyrimidin-7-yl-amine as colourless crystals, m.p. >250°.

Example 112

15 3-Benzenesulphonyl-2-ethyl-N5,N5-dimethyl-pyrazolo[1,5-a]pyrimidine-5,7-diamine and
3-benzenesulphonyl-N5-(2-dimethylamino-ethyl)-2-ethyl-pyrazolo[1,5-a]pyrimidine-5,7-diamine

[0148] 0.73 g (6.68 mmol) of 2-dimethylaminoethylamine in 5 ml of DMF was added to a solution of 0.45 g (1.3 mmol) of 3-benzenesulphonyl-5-chloro-2-ethyl-pyrazolo[1,5-a]pyrimidin-7-ylamine in 10 ml of DMF and stirred at 90° for 1 hr. The reaction solution was evaporated and the residue was partitioned between H₂O and CH₂Cl₂. The aqueous phase was extracted three times with 80 ml of CH₂Cl₂. The combined organic phases were dried (MgSO₄), filtered and evaporated. Subsequent chromatography (silica gel, CH₂Cl₂/MeOH/NH₄OH 65:10:1) yielded 0.12 g (26%) 3-benzenesulphonyl-2-ethyl-N5,N5-dimethyl-pyrazolo[1,5-a]pyrimidine-5,7-diamine as colourless crystals, m.p. 228-230°, and 0.09 g (17 %) 3-benzenesulphonyl-N5-(2-dimethylamino-ethyl)-2-ethyl-pyrazolo[1,5-a]pyrimidine-5,7-diamine as colourless crystals, m.p. 149.5-150.5°.

Example 1133-Benzenesulphonyl-5-dimethylaminomethyl-2-methylsulphanyl-pyrazolo[1,5-a]pyrimidin-7-ylamine

30

[0149]

a) 6.8 ml (50 mmol) of ethyl 4-chloro-acetoacetate were added to a solution of 13.5 mmol (50 mmol) of 4-benzenesulphonyl-5-methylsulphanyl-2H-pyrazol-3-ylamine in 80 ml of acetic acid and heated at reflux for 1.5 hrs. After cooling to RT the crystals obtained were filtered off, washed with EtOH and dried in a high vacuum at 50°. There were thus obtained 10.5 g (56%) of 3-benzenesulphonyl-5-chloromethyl-2-methylsulphanyl-pyrazolo[1,5-a]pyrimidin-7-ol as a colourless powder, m.p. 215-217°.

b) 5 ml of a 33% solution of dimethylamine in EtOH were added to a solution of 1.4 g (3.7 mmol) of 3-benzenesulphonyl-5-chloromethyl-2-methylsulphanyl-pyrazolo[1,5-a]pyrimidin-7-ol in 20 ml of DMF and stirred at RT for 4 hrs. The reaction solution was evaporated, the residue was partitioned between 0.5N NaOH and CH₂Cl₂. The aqueous phase was extracted three times with CH₂Cl₂. The combined organic phases were dried (MgSO₄), filtered and evaporated. Chromatography (SiO₂, CH₂Cl₂/MeOH 4:1) yielded 1.3 g (92%) of 3-benzenesulphonyl-5-dimethylaminomethyl-2-methylsulphanylpyrazolo[1,5-a]pyrimidin-7-ol as a beige powder, m.p. >220°.

c) A suspension of 1.3 g (3.43 mmol) of 3-benzenesulphonyl-5-dimethylaminomethyl-2-methylsulphanyl-pyrazolo[1,5-a]pyrimidin-7-ol in 50 ml of POCl₃ was heated at reflux for 3 hrs. The reaction solution was cooled to RT and evaporated. The residue was treated with 100 ml of ice-water and the pH value of the solution was adjusted to 8 with sat. NaHCO₃ solution. The aqueous phase was extracted three times with 100 ml of CH₂Cl₂ and the organic phases were dried (MgSO₄), filtered and evaporated. Chromatography (SiO₂, CH₂Cl₂/AcOEt 1:1) of the residue yielded 1.2 g (88%) of (3-benzenesulphonyl-7-chloro-2-methylsulphanyl-pyrazolo[1,5-a]pyrimidin-5-ylmethyl)-dimethyl-amine as a colourless foam.

d) 20 ml of a 50% solution of NH₃ in MeOH were added to a solution of 1.20 g (3 mmol) of (3-benzenesulphonyl-7-chloro-2-methylsulphanyl-pyrazolo[1,5-a]pyrimidin-5-ylmethyl)-dimethyl-amine in 30 ml of DMF and stirred at RT for 4 hrs. The reaction solution was evaporated and the residue was partitioned between 2N NaOH and CH₂Cl₂. The aqueous phase was extracted three times with CH₂Cl₂, and the combined organic phases were dried (MgSO₄), filtered and evaporated. Subsequent chromatography (silica gel, CH₂Cl₂/MeOH 6:1) yielded 0.90 g (78%) of 3-benzenesulphonyl-5-dimethylaminomethyl-2-methylsulphanyl-pyrazolo[1,5-a]pyrimidin-7-ylamine as colourless crystals, m.p. 216-218°.

Example 1143-Benzenesulphonyl-5-(4-methyl-piperazin-1-ylmethyl)-2-methylsulphanyl-pyrazolo[1,5-a]pyrimidin-7-ylamine

5 [0150]

- a) 1.57 ml (15.70 mmol) of 1-methyl-piperazine were added to a solution of 2.9 g (7.84 mmol) of 3-benzenesulphonyl-5-chloromethyl-2-methylsulphanyl-pyrazolo[1,5-a]pyrimidin-7-ol in 20 ml of DMF and stirred at RT for 4 hrs. The reaction solution was evaporated and the residue was partitioned between 0.5N NaOH and CH₂Cl₂. The aqueous phase was extracted three times with CH₂Cl₂. The combined organic phases were dried (MgSO₄), filtered and evaporated. Chromatography (SiO₂, CH₂Cl₂/MeOH 4:1) yielded 1.85 g (53%) of 3-benzenesulphonyl-5-(4-methyl-piperazin-1-ylmethyl)-2-methylsulphanyl-pyrazolo[1,5-a]pyrimidin-7-ol as a beige powder, m.p. >220°.
- b) A suspension of 4.0 g (9 mmol) of 3-benzenesulphonyl-5-(4-methyl-piperazin-1-ylmethyl)-2-methylsulphanyl-pyrazolo[1,5-a]pyrimidin-7-ol in 100 ml of POCl₃ was heated at reflux for 3 hrs. The reaction solution was cooled to RT and evaporated. The residue was treated with 100 ml of ice-water and the pH value of the solution was adjusted to 8 with sat. NaHCO₃ solution. The aqueous phase was extracted three times with 150 ml of CH₂Cl₂ and the organic phases were dried (MgSO₄), filtered and evaporated. Chromatography (SiO₂, CH₂Cl₂/MeOH 10:1) of the residue yielded 4.0 g (98%) of 3-benzenesulphonyl-7-chloro-5-(4-methyl-piperazin-1-ylmethyl)-2-methylsulphanyl-pyrazolo[1,5-a]pyrimidine as a pale brown powder, m.p. 113-116°.
- c) 10 ml of a 50% solution of NH₃ in MeOH were added to a solution of 0.8 g (1.77 mmol) of 3-benzenesulphonyl-7-chloro-5-(4-methyl-piperazin-1-ylmethyl)-2-methylsulphanylpyrazolo[1,5-a]pyrimidine in 20 ml of DMF and stirred at RT for 4 hrs. The reaction solution was evaporated and the residue was partitioned between 2N NaOH and CH₂Cl₂. The aqueous phase was extracted three times with CH₂Cl₂, and the combined organic phases were dried (MgSO₄), filtered and evaporated. Subsequent chromatography (SiO₂, CH₂Cl₂/MeOH/NH₄OH 90:10:1) yielded 0.59 g (77%) of 3-benzenesulphonyl-5-(4-methyl-piperazin-1-ylmethyl)-2-methylsulphanyl-pyrazolo[1,5-a]pyrimidin-7-ylamine as colourless crystals, m.p. 203-205°.

Example 11530 3-Benzenesulphonyl-7-(4-methyl-piperazin-1-yl)-5-(4-methyl-piperazin-1-ylmethyl)-2-methylsulphanyl-pyrazolo[1,5-a]pyrimidine

- [0151] 0.4 g (4 mmol) of 1-methyl-piperazine was added to a solution of 0.8 g (1.77 mmol) of 3-benzenesulphonyl-7-chloro-5-(4-methyl-piperazin-1-ylmethyl)-2-methylsulphanylpyrazolo[1,5-a]pyrimidine in 20 ml of DMF and stirred at RT for 6 hrs. The reaction solution was evaporated and the residue was partitioned between 2N NaOH and CH₂Cl₂. The aqueous phase was extracted three times with CH₂Cl₂, and the combined organic phases were dried (MgSO₄), filtered and evaporated. Subsequent chromatography (SiO₂, CH₂Cl₂/MeOH/NH₄OH 80:10:1) and crystallization from EtOH yielded 0.75 g (82%) of 3-benzenesulphonyl-7-(4-methyl-piperazin-1-yl)-5-(4-methyl-piperazin-1-ylmethyl)-2-methylsulphanyl-pyrazolo[1,5-a]pyrimidine as colourless crystals, m.p. 193-195°.

Example 1163-Benzenesulphonyl-5-(4-methyl-piperazin-1-ylmethyl)-2-methylsulphanyl-pyrazolo[1,5-a]pyrimidin-7-ylamine

45 [0152]

- a) 1 ml (6 mmol) of morpholine was added to a solution of 2.0 g (5.40 mmol) of 3-benzenesulphonyl-5-chloromethyl-2-methylsulphanyl-pyrazolo[1,5-a]pyrimidin-7-ol in 20 ml of DMF and stirred at RT for 4 hrs. The reaction solution was evaporated and the residue was partitioned between 0.5N NaOH and CH₂Cl₂. The aqueous phase was extracted three times with CH₂Cl₂. The combined organic phases were dried (MgSO₄), filtered and evaporated. Chromatography (SiO₂, CH₂Cl₂/MeOH 10:1) yielded 2.0 g (88%) of 3-benzenesulphonyl-2-methylsulphanyl-5-morpholin-4-ylmethyl-pyrazolo[1,5-a]pyrimidin-7-ol as a beige foam.
- b) A suspension of 2.0 g (4.75 mmol) of 3-benzenesulphonyl-2-methylsulphanyl-5-morpholin-4-ylmethyl-pyrazolo[1,5-a]pyrimidin-7-ol in 30 ml of POCl₃ was heated at reflux for 3 hrs. The reaction solution was cooled to RT and evaporated. The residue was treated with 100 ml of ice-water and the pH value of the solution was adjusted to 8 with sat. NaHCO₃ solution. The aqueous phase was extracted three times with 70 ml of CH₂Cl₂ and the organic phases were dried (MgSO₄), filtered and evaporated. Chromatography (SiO₂, CH₂Cl₂/MeOH 10:1) of the residue yielded 1.8 g (86%) of 3-benzenesulphonyl-7-chloro-2-methylsulphanyl-5-morpholin-4-ylmethyl-pyrazolo[1,5-a]

pyrimidine as a pale brown powder, m.p. 174-176°.

c) 10 ml of a 50% solution of NH_3 in MeOH were added to a solution of 0.9 g (2 mmol) of 3-benzenesulphonyl-7-chloro-2-methylsulphonyl-5-morpholin-4-ylmethyl-pyrazolo[1,5-a]pyrimidine in 20 ml of DMF and stirred at RT for 4 hrs. The DMF was evaporated in a high vacuum and the residue was partitioned between 2N NaOH and CH_2Cl_2 . The aqueous phase was extracted three times with CH_2Cl_2 and the combined organic phases were dried (MgSO_4), filtered and evaporated. Subsequent chromatography (silica gel, $\text{CH}_2\text{Cl}_2/\text{MeOH}/\text{NH}_4\text{OH}$ 80:10:1) and crystallization from EtOH yielded 0.70 g (83%) of 3-benzenesulphonyl-5-(4-methyl-piperazin-1-ylmethyl)-2-methylsulphonyl-pyrazolo[1,5-a]pyrimidin-7-ylamine as colourless crystals, m.p. 224-226°.

Example 117

3-Benzenesulphonyl-7-(4-methyl-piperazin-1-yl)-2-methylsulphonyl-5-morpholin-4-ylmethyl-pyrazolo[1,5-a]pyrimidine

[0153] 0.4 g (4 mmol) of 1-methyl-piperazine was added to a solution of 0.9 g (2 mmol) of 3-benzenesulphonyl-7-chloro-2-methylsulphonyl-5-morpholin-4-ylmethyl-pyrazolo[1,5-a]pyrimidine in 20 ml of DMF and stirred at RT for 4 hrs. The reaction solution was evaporated and the residue was partitioned between 2N NaOH and CH_2Cl_2 . The aqueous phase was extracted three times with CH_2Cl_2 and the combined organic phases were dried (MgSO_4), filtered and evaporated. Subsequent chromatography (SiO_2 , $\text{CH}_2\text{Cl}_2/\text{MeOH}/\text{NH}_4\text{OH}$ 80:1:1) and crystallization from EtOH yielded 0.80 g (77%) of 3-benzenesulphonyl-7-(4-methyl-piperazin-1-yl)-2-methylsulphonyl-5-morpholin-4-ylmethylpyrazolo[1,5-a]pyrimidine as colourless crystals, m.p. 199-201°.

Example 118

2-(3-Benzenesulphonyl-5-methyl-2-methylsulphonyl-pyrazolo[1,5-a]pyrimidin-7-yloxy)-ethyl]-dimethyl-amine

[0154] 0.28 ml (2.38 mmol) of 2-dimethylaminoethanol and 3.68 g of Cs_2CO_3 were added to a solution of 0.8 g (2.26 mmol) of 3-benzenesulphonyl-7-chloro-5-methyl-2-methylsulphonyl-pyrazolo[1,5-a]pyrimidine in 40 ml of acetonitrile and the suspension was stirred at RT for 12 hrs. The reaction mixture was poured into semi-concentrated aqueous sodium chloride solution and extracted three times with ethyl acetate. The combined organic phases were dried (MgSO_4), filtered and evaporated. Subsequent chromatography yielded 0.65 g (70%) of 2-(3-benzenesulphonyl-5-methyl-2-methylsulphonyl-pyrazolo[1,5-a]pyrimidin-7-yloxy)-ethyl]-dimethyl-amine as a pale yellow solid, m.p. 176-178°.

Example 119

3-Benzenesulphonyl-5-methyl-2-methylsulphonyl-7-(2-morpholin-4-yl-ethoxy)-pyrazolo[1,5-a]pyrimidine

[0155] In an analogous manner to that described in Example 122, from 3-benzenesulphonyl-7-chloro-5-methyl-2-methylsulphonyl-pyrazolo[1,5-a]pyrimidine and N-(2-hydroxy-ethyl)-morpholine there was obtained 3-benzenesulphonyl-5-methyl-2-methylsulphonyl-7-(2-morpholin-4-yl-ethoxy)-pyrazolo[1,5-a]pyrimidine as a pale yellow solid.

Example 120

8-Benzenesulphonyl-7-methylsulphonyl-pyrazolo[1,5-a][1,3,5]triazin-4-ylamine

[0156] 0.10 g (0.37 mmol) of 5-amino-3-methylthio-4-phenylsulphonyl-pyrazole was mixed with 0.25 g (2.55 mmol) of ethyl N-cyano-methanimide and stirred at 100°C for 16 hrs. The resulting pale beige paste was taken up in AcOEt/MeOH and treated in an ultrasound bath. The thus-obtained suspension was filtered. Chromatography (SiO_2 , $\text{CH}_2\text{Cl}_2/\text{MeOH}$ 95:5) yielded 0.052 g (44%) of 8-benzenesulphonyl-7-methylsulphonyl-pyrazolo[1,5-a][1,3,5]-triazin-4-ylamine as pale beige crystals, m.p. >280°C.

Example 121

(8-Benzenesulphonyl-2-methyl-7-methylsulphonyl-pyrazolo[1,5-a][1,3,5]triazin-4-yl)-methylamine

[0157]

a) A solution of 0.54 g (2 mol) of 5-amino-3-methylthio-4-phenylsulphonyl-pyrazole and 0.54 g (3.4 mmol) of ethyl

1-ethoxy-ethylidene-carbamate in acetic acid was stirred at 100°C for 3 hrs. After cooling to RT the precipitate was filtered off, washed off with a copious amount of Et₂O and dried in a high vacuum at 45°C. There was obtained 0.41 g (61%) of 8-benzenesulphonyl-2-methyl-7-methylsulphanyl-3H-pyrazolo[1,5-a][1,3,5]-triazin-4-one as white crystals, m.p. >300°C.

b) A suspension of 0.36 g (1 mmol) of 8-benzenesulphonyl-2-methyl-7-methylsulphanyl-3H-pyrazolo[1,5-a][1,3,5]triazin-4-one in 20 ml of POCl₃ was treated with 0.12 ml (1.5 mmol) of pyridine and heated 110°C for 3 hrs. The reaction solution was cooled to RT and evaporated. The residue was dried azeotropically twice with 50 ml of toluene each time. The thus-obtained residue was taken in 10 ml of 2N methylamine in tetrahydrofuran and stirred at room temperature for 4 hrs. The reaction solution was evaporated and partitioned between H₂O and AcOEt. The organic phase was washed with H₂O and sat. NaCl solution, dried (MgSO₄), filtered and evaporated. Chromatography (SiO₂, AcOEt/hexane 1:1) yielded 0.28 g (80%) of (8-benzenesulphonyl-2-methyl-7-methylsulphanyl-pyrazolo[1,5-a][1,3,5]triazin-4-yl)-methylamine as white crystals, m.p. 285° (dec).

Example 122

(8-Benzenesulphonyl-2-methyl-7-methylsulphanyl-pyrazolo[1,5-a][1,3,5]triazin-4-yl)-dimethylamine

[0158] In an analogous manner to that described in Example 123 b), from 8-benzenesulphonyl-2-methyl-7-methylsulphanyl-3H-pyrazolo[1,5-a][1,3,5]triazin-4-one and dimethylamine there was obtained (8-benzenesulphonyl-2-methyl-7-methylsulphanyl-pyrazolo[1,5-a][1,3,5]triazin-4-yl)-dimethylamine as pale pink coloured crystals, m.p. 228-230°.

Example 123

(8-Benzenesulphonyl-2-methyl-7-methylsulphanyl-pyrazolo[1,5-a][1,3,5]triazin-4-yl)-N',N'-dimethyl-propan-1,3-diamine

[0159] In an analogous manner to that described in Example 123 b), from 8-benzenesulphonyl-2-methyl-7-methylsulphanyl-3H-pyrazolo[1,5-a][1,3,5]triazin-4-one and 3-dimethylamino-1-propylamine there was obtained (8-benzenesulphonyl-2-methyl-7-methylsulphanyl-pyrazolo[1,5-a][1,3,5]triazin-4-yl)-N',N'-dimethyl-propan-1,3-diamine which was converted with HCl/diethyl ether into the corresponding hydrochloride (1:1.75), m.p. 249-250°.

Example 124

8-Benzenesulphonyl-2-methyl-4-(4-methylpiperazin-1-yl)-7-methylsulphanyl-pyrazolo[1,5-a][1,3,5]triazine

[0160] In an analogous manner to that described in Example 123 b), from 8-benzenesulphonyl-2-methyl-7-methylsulphanyl-3H-pyrazolo[1,5-a][1,3,5]triazin-4-one and 1-methyl-piperazine there was obtained 8-benzenesulphonyl-2-methyl-4-(4-methyl-piperazin-1-yl)-7-methylsulphanyl-pyrazolo[1,5-a][1,3,5]triazine as yellow crystals, m.p. 169-171°.

Example 125

8-Benzenesulphonyl-2-methyl-4-(4-benzylpiperazin-1-yl)-7-methylsulphanyl-pyrazolo[1,5-a][1,3,5]triazine

[0161] In an analogous manner to that described in Example 123 b), from 8-benzenesulphonyl-2-methyl-7-methylsulphanyl-3H-pyrazolo[1,5-a][1,3,5]triazin-4-one and 1-benzylpiperazine there was obtained 8-benzenesulphonyl-2-methyl-4-(4-benzylpiperazin-1-yl)-7-methylsulphanyl-pyrazolo[1,5-a][1,3,5]triazine as beige crystals, m.p. 190-192°.


Example A

[0162] Tablets of the following composition are produced in the usual manner:


	mg/tablet
Active ingredient	100
Powd. lactose	95
White corn starch	35

(continued)

	mg/tablet
Polyvinylpyrrolidone	8
Na carboxymethylstarch	10
Magnesium stearate	2
Tablet weight	250

Claims**1. Compounds of the general formulae**

and



wherein

- R¹ signifies phenyl, optionally substituted by one or more C₁₋₇-alkyl, halogen or C₁₋₇-alkoxy or is tolyl, pyridyl, naphthyl or thiophenyl;
- R² signifies hydrogen, C₁₋₇-alkyl, C₁₋₇-thioalkyl or hydroxy-C₁₋₇-alkoxy;
- R³ signifies amino, C₁₋₇-alkylamino, di-C₁₋₇-alkyl-amino, piperazinyl, optionally substituted by one or more C₁₋₇-alkyl, benzyl, phenyl or hydroxy-C₁₋₇-alkyl or is morpholinyl, imidazolyl, (CH₃)₂N(CH₂)_nNH-, (CH₃)₂N(CH₂)_nO- or morpholinyl-(CH₂)_nO- in which n signifies 2 or 3;
- R⁴ signifies hydrogen, C₁₋₇-alkyl or hydroxy-C₁₋₇-alkyl;
- R⁵ signifies hydrogen, halogen, C₁₋₇-alkyl, C₃₋₆-cycloalkyl, C₁₋₇-alkyl-C₁₋₇-alkoxy, OH-CH₂-CH₂-O-, (CH₃)₂N(CH₂)_nNH-, piperazinyl, optionally substituted by C₁₋₇-alkyl or is methyl-piperazinyl, optionally substituted by C₁₋₇-alkyl or is morpholinyl, methyl-morpholinyl, di-C₁₋₇-alkylamino or di-C₁₋₇-alkylamino-C₁₋₇-alkyl, or
- R⁴ and R⁵ together signify a group -(CH₂)_m- or -CH₂-S-CH₂- with m = or 4,

as well as their pharmaceutically acceptable salts.

2. Compounds of general formula I-A according to claim 1, wherein R³ signifies amino.**3. The following compounds in accordance with claim 2:**

3-benzenesulphonyl-5-methyl-2-methylsulphanyl-pyrazolo[1,5-a]pyrimidin-7-ylamine,
 3-(4-isopropyl-benzenesulphonyl)-5-methyl-2-methylsulphanyl-pyrazolo[1,5-a]pyrimidin-7-ylamine,
 5-methyl-2-methylsulphanyl-3-(naphthalene-2-sulphonyl)-pyrazolo[1,5-a]pyrimidin-7-ylamine,
 3-(4-fluoro-benzenesulphonyl)-5-methyl-2-methylsulphanyl-pyrazolo[1,5-a]pyrimidin-7-ylamine,
 3-benzenesulphonyl-5-cyclopropyl-2-methylsulphanyl-pyrazolo[1,5-a]pyrimidin-7-ylamine,
 3-benzenesulphonyl-2-methylsulphanyl-6,7-dihydro-5H-cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-ylamine,
 3-benzenesulphonyl-5-isopropyl-2-methylsulphanyl-pyrazolo[1,5-a]pyrimidin-7-ylamine,
 5-methyl-2-methylsulphanyl-3-(toluene-2-sulphonyl)-pyrazolo[1,5-a]pyrimidin-7-ylamine,

5-methyl-2-methylsulphanyl-3-(toluene-3-sulphonyl)-pyrazolo[1,5-a]pyrimidin-7-ylamine,
 3-benzenesulphonyl-5-methoxymethyl-2-methylsulphanyl-pyrazolo[1,5-a]pyrimidin-6-ylamine,
 3-benzenesulphonyl-N5,N5-dimethyl-2-methylsulphanyl-pyrazolo[1,5-a]pyrimidine-5,7-diamine,
 3-benzenesulphonyl-N5-(2-dimethylamino-ethyl)-2-methylsulphanyl-pyrazolo[1,5-a]pyrimidine-5,7-diamine,
 3-benzenesulphonyl-5-(4-methyl-piperazin-1-yl)-2-methylsulphanyl-pyrazolo[1,5-a]pyrimidin-7-ylamine and
 3-benzenesulphonyl-5-dimethylaminomethyl-2-methylsulphanyl-pyrazolo[1,5-a]pyrimidin-7-ylamine.

4. Compounds of general formula I-A in accordance with claim 1, wherein R³ signifies piperazinyl.

5. The following compounds in accordance with claim 4:

3-benzenesulphonyl-5-methyl-2-methylsulphanyl-7-piperazin-1-yl-pyrazolo[1,5-a]pyrimidine,
 3-(4-tert-butyl-benzenesulphonyl)-5-methyl-2-methylsulphanyl-7-piperazin-1-yl-pyrazolo[1,5-a]pyrimidine,
 3-benzenesulphonyl-5,6-dimethyl-2-methylsulphanyl-7-piperazin-1-yl-pyrazolo[1,5-a]pyrimidine,
 3-benzenesulphonyl-2-methylsulphanyl-7-piperazin-1-yl-5-propyl-pyrazolo[1,5-a]pyrimidine,
 3-benzenesulphonyl-5-cyclopropyl-2-methylsulphanyl-7-piperazin-1-yl-pyrazolo[1,5-a]pyrimidine,
 3-benzenesulphonyl-2-methylsulphanyl-8-piperazin-1-yl-6,7-dihydro-5H-cyclopenta[d]pyrazolo[1,5-a]pyrimidine,
 3-benzenesulphonyl-2-methylsulphanyl-8-piperazin-1-yl-5H,7H-pyrazolo[1,5-a]-thieno[3,4-d]pyrimidine,
 5-methyl-2-methylsulphanyl-7-piperazin-1-yl-3-(thiophene-2-sulphonyl)-pyrazolo[1,5-a]pyrimidine,
 3-benzenesulphonyl-2-ethyl-8-piperazin-1-yl-6,7-dihydro-5H-cyclopenta[d]pyrazolo[1,5-a]pyrimidine and
 5-methyl-2-methylsulphanyl-7-piperazin-1-yl-3-(toluene-2-sulphonyl)-pyrazolo[1,5-a]pyrimidine.

6. Compounds of general formula I-A in accordance with claim 1, wherein R³ signifies methylpiperazinyl.

7. The following compounds in accordance with claim 6:

3-benzenesulphonyl-5-cyclopropyl-2-methylsulphanyl-7-(4-methylpiperazin-1-yl)-pyrazolo[1,5-a]pyrimidine,
 3-benzenesulphonyl-8-(4-methyl-piperazin-1-yl)-2-methylsulphanyl-6,7-dihydro-5H-cyclopenta[d]pyrazolo
 [1,5-a]pyrimidine,
 3-benzenesulphonyl-8-(4-methyl-piperazin-1-yl)-2-methylsulphanyl-5H,7H-pyrazolo[1,5-a]thieno[3,4-d]pyri-
 midine,
 3-benzenesulphonyl-5-isopropyl-7-(4-methyl-piperazin-1-yl)-2-methylsulphanyl-pyrazolo[1,5-a]pyrimidine
 and
 2-[3-benzenesulphonyl-7-(4-methyl-piperazin-1-yl)-2-methylsulphanyl-pyrazolo[1,5-a]pyrimidine-5-yloxy]-
 ethanol.

8. Compounds of general formula I-B in accordance with claim 1, wherein R³ signifies amino or methylpiperazinyl.

9. The following compounds in accordance with claim 8:


8-benzenesulphonyl-7-methylsulphanyl-pyrazolo[1,5-a][1,3,5]triazin-4-ylamine and
 8-benzenesulphonyl-2-methyl-4-(4-methylpiperazin-1-yl)-7-methylsulphanyl-pyrazolo[1,5-a][1,3,5]triazine.

10. A medicament containing a compound according to any one of claims 1-9 and a therapeutically inert carrier material.


11. A medicament based on a compound of formula I-A or I-B according to any one of claims 1-9 and its pharmaceutically acceptable acid addition salts for the treatment or prevention of central nervous disorders such as psychoses, schizophrenia, manic depressions, depressions, neurological disorders, memory disorders, Parkinson's disease, amyotrophic lateral sclerosis, Alzheimer's disease and Huntington's chorea.

12. A process for the manufacture of compounds of formulae I-A and I-B according to claim 1, which process comprises

a) reacting a compound of the formula



or a compound of the formula



with a compound of the formula




wherein R¹-R⁵ have the significances given in claim,
and, if desired, converting a compound of general formula I-A or I-B into a pharmaceutically acceptable salt.

13. Compounds according to any one of claims 1-9 for use as therapeutically active substances.

14. The use of compounds according to any one of claims 1-9 and of pharmaceutically useable salts thereof, especially for the treatment or prevention of central nervous disorders such as psychoses, schizophrenia, manic depressions, depressions, neurological disorders, memory disorders, Parkinson's disease, amyotrophic lateral sclerosis, Alzheimer's disease and Huntington's chorea or for the production of corresponding medicaments.

Patentansprüche

1. Verbindungen der allgemeinen Formeln



worin

R¹ Phenyl, gegebenenfalls substituiert mit einem oder mehreren C₁₋₇-Alkyl, Halogen oder C₁₋₇-Alkoxy, bedeutet oder Toly, Pyridyl, Naphthyl oder Thiophenyl darstellt;

- R² Wasserstoff, C₁₋₇-Alkyl, C₁₋₇-Thioalkyl oder HydroxyC₁₋₇-alkoxy bedeutet;
 R³ Amino, C₁₋₇-Alkylamino, Di-C₁₋₇-alkylamino, Piperazinyl, gegebenenfalls substituiert mit einem oder mehreren C₁₋₇-Alkyl, Benzyl, Phenyl oder HydroxyC₁₋₇-alkyl, bedeutet oder Morpholinyl, Imidazolyl, (CH₃)₂N(CH₂)_nNH-, (CH₃)₂N(CH₂)_nO- oder Morpholinyl-(CH₂)_nO- darstellt, worin n 2 oder 3 ist;
 5 R⁴ Wasserstoff, C₁₋₇-Alkyl oder Hydroxy-C₁₋₇-alkyl bedeutet;
 R⁵ Wasserstoff, Halogen, C₁₋₇-Alkyl, C₃₋₆-Cycloalkyl, C₁₋₇-Alkyl-C₁₋₇-alkoxy, OH-CH₂-CH₂-O-, (CH₃)₂N(CH₂)_nNH-, Piperazinyl, gegebenenfalls substituiert mit C₁₋₇-Alkyl, bedeutet oder Methylpiperazinyl, gegebenenfalls substituiert mit C₁₋₇-Alkyl, bedeutet oder Morpholinyl, Methylmorpholinyl, Di-C₁₋₇-alkylamino oder Di-C₁₋₇-alkylamino-C₁₋₇-alkyl darstellt, oder
 10 R⁴ und R⁵ zusammen eine Gruppe -(CH₂)_m- oder -CH₂-S-CH₂- mit m = 3 oder 4 bedeutet,

sowie deren pharmazeutisch verträgliche Salze.

2. Verbindungen der allgemeinen Formel I-A nach Anspruch 1, worin R³ Amino bedeutet.

3. Verbindungen nach Anspruch 2, nämlich:

3-Benzolsulfonyl-5-methyl-2-methylsulfanyl-pyrazolo[1,5-a]pyrimidin-7-ylamin,
 3-(4-Isopropyl-benzolsulfonyl)-5-methyl-2-methylsulfanyl-pyrazolo[1,5-a]pyrimidin-7-ylamin,
 5-Methyl-2-methylsulfanyl-3-(naphthalin-2-sulfonyl)-pyrazolo[1,5-a]pyrimidin-7-ylamin,
 3-(4-Fluor-benzolsulfonyl)-5-methyl-2-methylsulfanyl-pyrazolo[1,5-a]pyrimidin-7-ylamin,
 3-Benzolsulfonyl-5-cyclopropyl-2-methylsulfanyl-pyrazolo[1,5-a]pyrimidin-7-ylamin,
 3-Benzolsulfonyl-2-methylsulfanyl-6,7-dihydro-5H-cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-ylamin,
 3-Benzolsulfonyl-5-isopropyl-2-methylsulfanyl-pyrazolo[1,5-a]pyrimidin-7-ylamin,
 5-Methyl-2-methylsulfanyl-3-(toluol-2-sulfonyl)-pyrazolo[1,5-a]pyrimidin-7-ylamin,
 5-Methyl-2-methylsulfanyl-3-(toluol-3-sulfonyl)-pyrazolo[1,5-a]pyrimidin-7-ylamin,
 3-Benzolsulfonyl-5-methoxymethyl-2-methylsulfanyl-pyrazolo[1,5-a]pyrimidin-6-ylamin,
 3-Benzolsulfonyl-N5,N5-dimethyl-2-methylsulfanyl-pyrazolo[1,5-a]pyrimidin-5,7-diamin,
 3-Benzolsulfonyl-N5-(2-dimethylamino-ethyl)-2-methylsulfanyl-pyrazolo[1,5-a]pyrimidin-5,7-diamin,
 3-Benzolsulfonyl-5-(4-methylpiperazin-1-yl)-2-methylsulfanyl-pyrazolo[1,5-a]pyrimidin-7-ylamin und
 3-Benzolsulfonyl-5-dimethylaminomethyl-2-methylsulfanyl-pyrazolo[1,5-a]pyrimidin-7-ylamin.

4. Verbindungen der allgemeinen Formel I-A nach Anspruch 1, worin R³ Piperazinyl bedeutet.

5. Verbindungen nach Anspruch 4, nämlich:

3-Benzolsulfonyl-5-methyl-2-methylsulfanyl-7-piperazin-1-ylpyrazolo[1,5-a]pyrimidin,
 3-(4-tert-Butyl-benzolsulfonyl)-5-methyl-2-methylsulfanyl-7-piperazin-1-yl-pyrazolo[1,5-a]pyrimidin,
 3-Benzolsulfonyl-5,6-dimethyl-2-methylsulfanyl-7-piperazin-1-yl-pyrazolo[1,5-a]pyrimidin,
 3-Benzolsulfonyl-2-methylsulfanyl-7-piperazin-1-yl-5-propyl-pyrazolo[1,5-a]pyrimidin,
 3-Benzolsulfonyl-5-cyclopropyl-2-methylsulfanyl-7-piperazin-1-yl-pyrazolo[1,5-a]pyrimidin,
 3-Benzolsulfonyl-2-methylsulfanyl-8-piperazin-1-yl-6,7-dihydro-5H-cyclopenta[d]pyrazolo[1,5-a]pyrimidin,
 3-Benzolsulfonyl-2-methylsulfanyl-8-piperazin-1-yl-5H,7H-pyrazob[1,5-a]thieno[3,4-d]pyrimidin,
 5-Methyl-2-methylsulfanyl-7-piperazin-1-yl-3-(thiophen-2-sulfonyl)-pyrazolo[1,5-a]pyrimidin,
 3-Benzolsulfonyl-2-ethyl-8-piperazin-1-yl-6,7-dihydro-5H-cyclopenta[d]pyrazolo[1,5-a]pyrimidin und
 5-Methyl-2-methylsulfanyl-7-piperazin-1-yl-3-(toluol-2-sulfonyl)-pyrazolo[1,5-a]pyrimidin.

6. Verbindungen der allgemeinen Formel I-A nach Anspruch 1, worin R³ Methylpiperazinyl bedeutet.

7. Verbindungen nach Anspruch 6, nämlich:

3-Benzolsulfonyl-5-cyclopropyl-2-methylsulfanyl-7-(4-methylpiperazin-1-yl)pyrazolo[1,5-a]pyrimidin,
 3-Benzolsulfonyl-8-(4-methylpiperazin-1-yl)-2-methylsulfanyl-6,7-dihydro-5H-cyclopenta[d]pyrazolo[1,5-a]pyrimidin,
 3-Benzolsulfonyl-8-(4-methylpiperazin-1-yl)-2-methylsulfanyl-5H,7H-pyrazolo[1,5-a]thieno[3,4-d]pyrimidin,
 3-Benzolsulfonyl-5-isopropyl-7-(4-methylpiperazin-1-yl)-2-methylsulfanyl-pyrazolo[1,5-a]pyrimidin und
 2-[3-Benzolsulfonyl-7-(4-methylpiperazin-1-yl)-2-methylsulfanyl-pyrazolo[1,5-a]pyrimidin-5-yloxy]-ethanol.

8. Verbindungen der allgemeinen Formel I-B nach Anspruch 1, worin R³ Amino oder Methylpiperazinyl bedeutet.

9. Verbindungen nach Anspruch 8, nämlich:


8-Benzolsulfonyl-7-methylsulfonyl-pyrazolo[1,5-a][1,3,5]triazin-4-ylamin und
8-Benzolsulfonyl-2-methyl-4-(4-methylpiperazin-1-yl)-7-methylsulfonyl-pyrazolo[1,5-a][1,3,5]triazin.

10. Arzneimittel, enthaltend eine Verbindung nach einem der Ansprüche 1-9 und ein therapeutisch inertes Trägermaterial.


11. Arzneimittel, basierend auf einer Verbindung der Formel I-A oder I-B, nach einem der Ansprüche 1-9 und ihren pharmazeutisch verträglichen Säureadditionssalzen für die Behandlung oder Prävention von Störungen des zentralen Nervensystems, wie Psychosen, Schizophrenie, manische Depressionen, Depressionen, neurologische Störungen, Gedächtnisstörungen, Parkinson-Krankheit, amyotrophe laterale Sklerose, Alzheimer-Krankheit und Huntington Chorea.

12. Verfahren zur Herstellung von Verbindungen der Formeln I-A und I-B nach Anspruch 1, wobei das Verfahren umfasst

a) Umsetzen einer Verbindung der Formel



oder einer Verbindung der Formel



mit einer Verbindung der Formel




worin R¹-R⁵ die im Anspruch angegebenen Bedeutungen aufweisen und falls erwünscht, Umwandeln einer Verbindung der allgemeinen Formel I-A oder I-B in ein pharmazeutisch verträgliches Salz.

13. Verbindungen nach einem der Ansprüche 1-9 zur Verwendung als therapeutisch wirksame Substanzen.

14. Verwendung von Verbindungen nach einem der Ansprüche 1-9 und von pharmazeutisch brauchbaren Salzen davon, insbesondere für die Behandlung oder Prävention von Störungen des zentralen Nervensystems, wie Psychosen, Schizophrenie, manische Depressionen, Depressionen, neurologische Störungen, Gedächtnisstörungen, Parkinson-Krankheit, amyotrophe laterale Sklerose, Alzheimer-Krankheit und Huntington Chorea oder zur Herstellung von entsprechenden Arzneimitteln.

R revendications

1. Composés de formules générales



dans lesquelles

- R¹ représente un groupe phényle éventuellement substitué par un ou plusieurs atomes d'halogène ou groupes alkyle en C₁₋₇ ou alcoxy en C₁₋₇ ou est le groupe tolyle, pyridyle, naphtyle ou thiophényle ;
- R² représente un atome d'hydrogène ou un groupe alkyle en C₁₋₇, thioalkyle en C₁₋₇ ou hydroxy-alcoxy (C₁₋₇) ;
- R³ représente un groupe amino, alkyl(C₁₋₇)amino, dialkyl(C₁₋₇)amino, pipérazinyle, éventuellement substitué par un ou plusieurs groupes alkyle en C₁₋₇, benzyle, phényle ou hydroxyalkyle(C₁₋₇) ou est le groupe morpholinyle, imidazolyle, (CH₃)₂N(CH₂)_nNH-, (CH₃)₂N(CH₂)_nO- ou morpholinyl-(CH₂)_nO-, dans lequel n représente 2 ou 3 ;
- R⁴ représente un atome d'hydrogène ou un groupe alkyle en C₁₋₇ ou hydroxyalkyle(C₁₋₇) ;
- R⁵ représente un atome d'hydrogène ou d'halogène ou un groupe alkyle en C₁₋₇, cycloalkyle en C₃₋₆, alkyl(C₁₋₇)-alcoxy(C₁₋₇), OH-CH₂-CH₂-O-, (CH₃)₂N(CH₂)_nNH-, pipérazinyle, éventuellement substitué par un groupe alkyle en C₁₋₇, ou est le groupe méthylpipérazinyle éventuellement substitué par un groupe alkyle en C₁₋₇, ou est un groupe morpholinyle, méthylmorpholinyle, dialkyl(C₁₋₇)amino ou dialkyl(C₁₋₇)amino-alkyle(C₁₋₇), ou
- R⁴ et R⁵ représentent ensemble un groupe -(CH₂)_m- ou -CH₂-S-CH₂ où m = 3 ou 4,

ainsi que leurs sels pharmaceutiquement acceptables.

2. Composés de formule générale I-A selon la revendication 1, dans lesquels R³ représente le groupe amino.

3. Composés suivants selon la revendication 2:

3-benzènesulfonyl-5-méthyl-2-méthylsulfanylpirazolo[1,5-a]pyrimidin-7-ylamine,
 3-(4-isopropylbenzènesulfonyl-5-méthyl-2-méthylsulfanylpirazolo[1,5-a]pyrimidin-7-ylamine,
 5-méthyl-2-méthylsulfanyl-3-(naphtalène-2-sulfonyl)pyrazolo[1,5-a]pyrimidin-7-ylamine,
 3-(4-fluorobenzènesulfonyl)-5-méthyl-2-méthylsulfanylpirazolo[1,5-a]pyrimidin-7-ylamine,
 3-benzènesulfonyl-5-cyclopropyl-2-méthylsulfanylpirazolo[1,5-a]pyrimidin-7-ylamine,
 3-benzènesulfonyl-2-méthylsulfanyl-6,7-dihydro-5H-cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-ylamine,
 3-benzènesulfonyl-5-isopropyl-2-méthylsulfanylpirazolo[1,5-a]pyrimidin-7-ylamine,
 5-méthyl-2-méthylsulfanyl-3-(toluène-2-sulfonyl)pyrazolo[1,5-a]pyrimidin-7-ylamine,
 5-méthyl-2-méthylsulfanyl-3-(toluène-3-sulfonyl)pyrazolo[1,5-a]pyrimidin-7-ylamine,
 3-benzènesulfonyl-5-méthoxyméthyl-2-méthylsulfanylpirazolo[1,5-a]pyrimidin-6-ylamine,
 3-benzènesulfonyl-N5,N5-diméthyl-2-méthylsulfanylpirazolo[1,5-a]pyrimidine-5,7-diamine,
 3-benzènesulfonyl-N5-(2-diméthylaminoéthyl)-2-méthylsulfanylpirazolo[1,5-a]pyrimidine-5,7-diamine,
 3-benzènesulfonyl-5-(4-méthylpipérazin-1-yl)-2-méthylsulfanylpirazolo[1,5-a]pyrimidin-7-ylamine et
 3-benzènesulfonyl-5-diméthylaminométhyl-2-méthylsulfanylpirazolo[1,5-a]pyrimidin-7-ylamine.

4. Composés de formule générale I-A selon la revendication 1, dans lesquels R³ représente le groupe pipérazinyle.

5. Composés suivants selon la revendication 4:

3-benzènesulfonyl-5-méthyl-2-méthylsulfanyl-7-pipérazin-1-ylpyrazolo[1,5-a]pyrimidin ,
 3-(4-tert-butylbenzènesulfonyl)-5-méthyl-2-méthylsulfanyl-7-pipérazin-1-yl-pyrazolo[1,5-a]pyrimidine,
 3-benzènesulfonyl-5,6-diméthyl-2-méthylsulfanyl-7-pipérazin-1-ylpyrazolo[1,5-a]pyrimidine,
 3-benzènesulfonyl-2-méthylsulfanyl-7-pipérazin-1-yl-5-propylpyrazolo[1,5-a]pyrimidine,
 3-benzènesulfonyl-5-cyclopropyl-2-méthylsulfanyl-7-pipérazin-1-ylpyrazolo[1,5-a]pyrimidine,
 3-benzènesulfonyl-2-méthylsulfanyl-8-pipérazin-1-yl-6,7-dihydro-5H-cyclopenta[d]pyrazolo[1,5-a]pyrimidin ,
 3-benzènesulfonyl-2-méthylsulfanyl-8-pipérazin-1-yl-5H,7H-pyrazolo[1,5-a]thiéno[3,4-d]pyrimidine,
 5-méthyl-2-méthylsulfanyl-7-pipérazin-1-yl-3-(thiophène-2-sulfonyl)pyrazolo[1,5-a]pyrimidine,
 3-benzènesulfonyl-2-éthyl-8-pipérazin-1-yl-6,7-dihydro-5H-cyclopenta[d]pyrazolo[1,5-a]pyrimidine et
 5-méthyl-2-méthylsulfanyl-7-pipérazin-1-yl-3-(toluène-2-sulfonyl)pyrazolo[1,5-a]pyrimidine

6. Composés de formule générale I-A selon la revendication 1, dans lesquels R³ représente le groupe méthylpipérazinyle.

7. Composés suivants selon la revendication 6:

3-benzènesulfonyl-5-cyclopropyl-2-méthylsulfanyl-7-(4-méthylpipérazin-1-yl)-pyrazolo[1,5-a]pyrimidine,
 3-benzènesulfonyl-8-(4-méthylpipérazin-1-yl)-2-méthylsulfanyl-6,7-dihydro-5H-cyclopenta[d]pyrazolo[1,5-a]
 pyrimidine,
 3-benzènesulfonyl-8-(4-méthylpipérazin-1-yl)-2-méthylsulfanyl-5H,7H-pyrazolo[1,5-a]thiéno[3,4-d]pyrimidi-
 ne,
 3-benzènesulfonyl-5-isopropyl-7-(4-méthylpipérazin-1-yl)-2-méthylsulfanylpyrazolo[1,5-a]pyrimidine et
 2-[3-benzènesulfonyl-7-(4-méthylpipérazin-1-yl)-2-méthylsulfanylpyrazolo[1,5-a]pyrimidin-5-yloxy]éthanol.

8. Composés de formule générale I-B selon la revendication 1, dans lesquels R³ représente le groupe amino ou méthylpipérazinyle.

9. Composés suivants selon la revendication 8:


8-benzènesulfonyl-7-méthylsulfanylpyrazolo[1,5-a][1,3,5]triazin-4-ylamine et
 8-benzènesulfonyl-2-méthyl-4-(4-méthylpipérazin-1-yl)-7-méthylsulfanylpyrazolo[1,5-a][1,3,5]triazine.

10. Médicament contenant un composé selon l'une quelconque des revendications 1 à 9 et une substance en tant que véhicule thérapeutiquement inerte.


11. Médicament à base d'un composé de formule I-A ou I-B selon l'une quelconque des revendications 1 à 9, et ses sels d'addition avec des acides pharmaceutiquement acceptables, pour le traitement ou la prévention de troubles du système nerveux central tels que les psychoses, la schizophrénie, les psychoses maniaco-dépressives, les dépressions, les troubles neurologiques, les troubles de la mémoire, la maladie de Parkinson, la sclérose latérale amyotrophique, la maladie d'Alzheimer et la chorée de Huntington.

12. Procédé pour la préparation de composés de formules I-A et I-B selon la revendication 1, lequel procédé comprend

a) la mise en réaction d'un composé de formule



ou d'un composé de formule



XIV

avec un composé de formule



dans laquelle R^1 - R^5 ont les significations données dans la revendication, et, si on le désire, la conversion d'un composé de formule générale I-A ou I-B en un sel pharmaceutiquement acceptable.

13. Composés selon l'une quelconque des revendications 1 à 9, pour utilisation en tant que substances thérapeutiquement actives.

14. Utilisation des composés selon l'une quelconque des revendications 1 à 9 et de leurs sels pharmaceutiquement utilisables, en particulier pour le traitement ou la prévention de troubles du système nerveux central tels que les psychoses, la schizophrénie, les psychoses maniaco-dépressives, les dépressions, les troubles neurologiques, les troubles de la mémoire, la maladie de Parkinson, la sclérose latérale amyotrophique, la maladie d'Alzheimer et la chorée de Huntington, ou pour la fabrication de médicaments correspondants.